WO2011004192A1 - Animal models and therapeutic molecules - Google Patents
Animal models and therapeutic molecules Download PDFInfo
- Publication number
- WO2011004192A1 WO2011004192A1 PCT/GB2010/051122 GB2010051122W WO2011004192A1 WO 2011004192 A1 WO2011004192 A1 WO 2011004192A1 GB 2010051122 W GB2010051122 W GB 2010051122W WO 2011004192 A1 WO2011004192 A1 WO 2011004192A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- regions
- mammal
- cell
- light chain
- Prior art date
Links
- 238000010171 animal model Methods 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 68
- 210000004027 cell Anatomy 0.000 claims description 194
- 108020004414 DNA Proteins 0.000 claims description 185
- 238000003780 insertion Methods 0.000 claims description 142
- 230000037431 insertion Effects 0.000 claims description 142
- 238000011144 upstream manufacturing Methods 0.000 claims description 91
- 239000012634 fragment Substances 0.000 claims description 66
- 241000124008 Mammalia Species 0.000 claims description 36
- 230000006798 recombination Effects 0.000 claims description 28
- 238000005215 recombination Methods 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 108091026890 Coding region Proteins 0.000 claims description 16
- 238000002744 homologous recombination Methods 0.000 claims description 14
- 230000006801 homologous recombination Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 abstract description 74
- 239000000203 mixture Substances 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 78
- 108090000623 proteins and genes Proteins 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 28
- 239000003550 marker Substances 0.000 description 28
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 24
- 238000012986 modification Methods 0.000 description 21
- 230000004048 modification Effects 0.000 description 21
- 230000000977 initiatory effect Effects 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 210000004602 germ cell Anatomy 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- 241000894007 species Species 0.000 description 15
- 239000013615 primer Substances 0.000 description 14
- 230000009261 transgenic effect Effects 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 108700024394 Exon Proteins 0.000 description 10
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 10
- 108010091086 Recombinases Proteins 0.000 description 10
- 102000018120 Recombinases Human genes 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 9
- 108091092195 Intron Proteins 0.000 description 9
- 230000002759 chromosomal effect Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 102000001183 RAG-1 Human genes 0.000 description 8
- 108060006897 RAG1 Proteins 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 7
- 108010020764 Transposases Proteins 0.000 description 7
- 102000008579 Transposases Human genes 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 229950010131 puromycin Drugs 0.000 description 6
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 238000011814 C57BL/6N mouse Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000003917 human chromosome Anatomy 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000012804 iterative process Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 2
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 2
- 241000484025 Cuniculus Species 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 241000577979 Peromyscus spicilegus Species 0.000 description 2
- 108700025866 RAG-1 Genes Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101000840273 Homo sapiens Immunoglobulin lambda constant 1 Proteins 0.000 description 1
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100029610 Immunoglobulin lambda constant 1 Human genes 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100058506 Mus musculus Bloc1s5 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Definitions
- the present invention relates inter alia to non-human animals and cells that are engineered to contain exogenous DNA, such as human immunoglobulin gene DNA, their use in medicine and the study of disease, methods for production of non human animals and cells, and antibodies and antibody chains produced by such animals and derivatives thereof.
- exogenous DNA such as human immunoglobulin gene DNA
- mice with human immune systems In order to get around the problems of humanizing antibodies a number of companies set out to generate mice with human immune systems. The strategy used was to knockout the heavy and light chain loci in ES cells and complement these genetic lesions with transgenes designed to express the human heavy and light chain genes. Although fully human antibodies could be generated, these models have several major limitations:
- WO2007117410 discloses chimaeric constructs for expressing chimaeric antibodies.
- WO2010039900 discloses knock in cells and mammals having a genome encoding chimaeric antibodies.
- the present invention provides, inter alia, a process for the generation in non-human mammals of antibodies that comprise a human Ig variable region, and further provides non-human animal models for the generation of such antibodies.
- the invention relates to a non-human mammal whose genome comprises:
- the invention relates to non-human mammal whose genome comprises
- the invention relates to non-human mammalian cell whose genome comprises
- the invention relates to a non-human mammalian cell whose genome comprises
- the invention relates to a method for producing a non-human cell or mammal comprising inserting into a non-human mammal cell genome, such as an ES cell genome;
- steps (b) optionally one or more human Ig light chain kappa V regions and one or more human Ig light chain kappa J regions upstream of the host non-human mammal kappa constant region and/or one or more human Ig light chain lambda V regions and one or more human Ig light chain lambda J regions upstream of the host non-human mammal lambda constant region; respectively, the insertion being such that the non-human cell or mammal is able to produce a repertoire of chimaeric antibodies having a non-human mammal constant region and a human variable region, wherein steps (a) and (b) can be carried out in either order and each of steps (a) and (b) can be carried out in a stepwise manner or as a single step.
- Insertion may be by homologous recombination.
- the invention relates to a method for producing an antibody or antibody chain specific to a desired antigen the method comprising immunizing a transgenic non-human mammal as disclosed herein with the desired antigen and recovering the antibody or antibody chain.
- the invention relates to a method for producing a fully humanised antibody comprising immunizing a transgenic non-human mammal as disclosed herein with the desired antigen, recovering the antibody or cells producing the antibody and then replacing the non- human mammal constant region with a human constant region, for example by protein or DNA engineering.
- the invention relates to humanised antibodies and antibody chains produced according to the present invention, both in chimaeric (for example, mouse-human) and fully humanised form, as well as fragments and derivatives of said antibodies and chains, and use of said antibodies, chains and fragments in medicine, including diagnosis.
- chimaeric for example, mouse-human
- fully humanised form as well as fragments and derivatives of said antibodies and chains, and use of said antibodies, chains and fragments in medicine, including diagnosis.
- the invention relates to use of a non-human mammal as described herein as a model for the testing of drugs and vaccines.
- Figures 1 - 8 show an iterative process for insertion of a series of human BACs into a mouse Ig locus.
- Figures 9 - 18 show in more detail the process of figures 1-8 for the IgH and kappa locus
- Figures 19 and 20 show the principles behind antibody generation in chimaeric mice.
- Figure 21 shows a possible insertion site for the human DNA in a mouse chromosome.
- Figures 22 - 26 disclose an alternative iterative process for insertion of a series of human BACs into a mouse Ig locus.
- Figure 27 - 29 illustrate a mechanism for inversion of the host VDJ region
- Figure 30 illustrates proof of principle for insertion of a plasmid using an RMCE approach.
- Figure 31 illustrates sequential RMCE - Integration into Landing Pad
- Figure 32 illustrates confirmation of Successful Insertion into Landing Pad
- Figure 33 illustrates PCR Confirmation of 3' End Curing
- Figure 34 illustrates insertion of BAC#1 and PCR Diagnostics
- nucleotide coordinates for the mouse are from NCBI m37, April 2007 ENSEMBL Release 55.37h for the mouse C57BL/6J strain.
- Human nucleotides are from GRCh37, Feb 2009 ENSEMBL Release 55.37 and rat from RGSC 3.4 Dec 2004 ENSEMBL release 55.34w.
- mice we disclose methods for the construction of chimaeric human heavy and light chain loci in a non-human mammal, for example a mouse.
- Reference to work in mice herein is by way of example only, and reference to mice is taken to include reference to all non-human mammals unless otherwise apparent from the disclosure, with mice being preferred as the non- human mammal.
- the invention relates to a non-human mammal whose genome comprises:
- the invention relates to a non-human mammal whose genome comprises:
- non-human mammal genome is modified to prevent expression of fully host- species specific antibodies.
- the inserted human DNA comprises at least 50% of the human heavy chain variable (V) genes, such as at least 60%, at least 70%, at least 80%, at least 90%, and in one aspect all of the human V genes.
- V human heavy chain variable
- the inserted human DNA comprises at least 50% of the human heavy chain diversity (D) genes, such as at least 60%, at least 70%, at least 80%, at least 90%, and in one aspect all of the human D genes.
- D human heavy chain diversity
- the inserted human DNA comprises at least 50% of the human heavy chain joining (J) genes, such as at least 60%, at least 70%, at least 80%, at least 90%, and in one aspect all of the human J genes.
- J human heavy chain joining
- the inserted human DNA comprises at least 50% of the human light chain Variable (V) genes, such as at least 60%, at least 70%, at least 80%, at least 90%, and in one aspect all of the human light chain V genes.
- V human light chain Variable
- the inserted human DNA comprises at least 50% of the human light chain joining (J) genes, such as at least 60%, at least 70%, at least 80%, at least 90%, and in one aspect all of the human light chain J genes.
- J human light chain joining
- the inserted human genes may be derived from the same individual or different individuals, or be synthetic or represent human consensus sequences. Although the number of V D and J regions is variable between human individuals, in one aspect there are considered to be 51 human V genes, 27 D and 6 J genes on the heavy chain, 40 human V genes and 5 J genes on the kappa light chain and 29 human V genes and 4 J genes on the lambda light chain (Janeway and Travers, Immunobiology, Third edition)
- the human heavy chain locus inserted into the non-human mammal contains the full repertoire of human V, D and J regions, which in the genome is in functional arrangement with the non-human mammal constant regions such that functional chimaeric antibodies can be produced between the human variable and non-human mammal constant regions.
- This total inserted human heavy chain genetic material is referred to herein as the human IgH VDJ region, and comprises DNA from a human genome that encodes all the exons encoding human V, D and J portions and suitably also the associated introns.
- reference to the human Ig light chain kappa V and J regions herein refers to human DNA comprising all the exons encoding V and J regions and suitably also the associated introns of the human genome.
- Reference to the human Ig light chain lambda V and J regions herein refers to human DNA comprising all the exons encoding V and J regions and suitably also the associated introns of the human genome.
- Human variable regions are suitably inserted upstream of non-human mammal constant region, the latter comprising all of the DNA required to encode the full constant region or a sufficient portion of the constant region to allow the formation of an effective chimaeric antibody capable of specifically recognising an antigen.
- the chimaeric antibodies or antibody chains have a part of a host constant region sufficient to provide one or more effector functions seen in antibodies occurring naturally in a host mammal, for example that they are able interact with Fc receptors, and/or bind to complement.
- references to a chimaeric antibody or antibody chain having a host non mammal constant region herein therefore is not limited to the complete constant region but also includes chimaeric antibodies or chains which have all of the host constant region, or a part thereof sufficient to provide one or more effector functions.
- This also applies to non human mammals and cells and methods of the invention in which human variable region DNA may be inserted into the host genome such that it forms a chimaeric antibody chain with all or part of a host constant region.
- the whole of a host constant region is operably linked to human variable region DNA.
- the host non-human mammal constant region herein is preferably the endogenous host wild-type constant region located at the wild type locus, as appropriate for the heavy or light chain.
- the human heavy chain DNA is suitably inserted on mouse chromosome 12, suitably adjacent the mouse heavy chain constant region.
- the insertion of the human DNA is targeted to the region between the J4 exon and the C ⁇ locus in the mouse genome IgH locus, and in one aspect is inserted between coordinates 114,667,090 and 114,665,190, suitably at coordinate 114,667,091.
- the insertion of the human DNA such as the human light chain kappa VJ is targeted into mouse chromosome 6 between coordinates 70,673,899 and 70,675,515, suitably at position 70,674,734, or an equivalent position in the lambda mouse locus on chromosome 16.
- the host non-human mammal constant region for forming the chimaeric antibody may be at a different (non endogenous) chromosomal locus.
- the inserted human DNA such as the human variable VDJ or VJ region(s) may then be inserted into the non-human genome at a site which is distinct from that of the naturally occurring heavy or light constant region.
- the native constant region may be inserted into the genome, or duplicated within the genome, at a different chromosomal locus to the native position, such that it is in a functional arrangement with the human variable region such that chimaeric antibodies of the invention can still be produced.
- the human DNA is inserted at the endogenous host wild-type constant region located at the wild type locus between the host constant region and the host VDJ region.
- variable region upstream of the non human mammal constant region means that there is a suitable relative location of the two antibody portions, variable and constant, to allow the variable and constant regions to form a chimaeric antibody or antibody chain in vivo in the mammal.
- the inserted human DNA and host constant region are in functional arrangement with one another for antibody or antibody chain production.
- the inserted human DNA is capable of being expressed with different host constant regions through isotype switching.
- isotype switching does not require or involve trans switching. Insertion of the human variable region DNA on the same chromosome as the relevant host constant region means that there is no need for trans-switching to produce isotype switching.
- the transgenic loci used for the prior art models were of human origin, thus even in those cases when the transgenes were able to complement the mouse locus so that the mice produced B-cells producing fully human antibodies, individual antibody affinities rarely reached those which could be obtained from intact (non-transgenic) animals.
- the principal reason for this is the fact that the control elements of the locus are human.
- the signalling components for instance to activate hyper-mutation and selection of high affinity antibodies are compromised.
- host non-human mammal constant regions are maintained and it is preferred that at least one non-human mammal enhancer or other control sequence, such as a switch region, is maintained in functional arrangement with the non-human mammal constant region, such that the effect of the enhancer or other control sequence, as seen in the host mammal, is exerted in whole or in part in the transgenic animal.
- at least one non-human mammal enhancer or other control sequence such as a switch region
- This approach above is designed to allow the full diversity of the human locus to be sampled, to allow the same high expression levels that would be achieved by non-human mammal control sequences such as enhancers, and is such that signalling in the B-cell, for example isotype switching using switch recombination sites, would still use non-human mammal sequences.
- a mammal having such a genome would produce chimaeric antibodies with human variable and non-human mammal constant regions, but these could be readily humanized, for example in a cloning step. Moreover the in vivo efficacy of these chimaeric antibodies could be assessed in these same animals.
- the inserted human IgH VDJ region comprises, in germline configuration, all of the V, D and J regions and intervening sequences from a human.
- 800-1000kb of the human IgH VDJ region is inserted into the non-human mammal IgH locus, and in one aspect a 940, 950 or 960 kb fragment is inserted.
- this includes bases 105,400,051 to 106,368,585 from human chromosome 14 (all coordinates refer to NCBI36 for the human genome, ENSEMBL Release 54 and NCBIM37 for the mouse genome, relating to mouse strain C57BL/6J).
- the inserted IgH human fragment consists of bases 105,400,051 to 106,368,585 from chromosome 14.
- the inserted human heavy chain DNA such as DNA consisting of bases 105,400,051 to 106,368,585 from chromosome 14 is inserted into mouse chromosome 12 between the end of the mouse J4 region and the E ⁇ region, suitably between coordinates 114,667,091 and 114,665,190, suitably at coordinate 114,667,091.
- the inserted human kappa VJ region comprises, in germline configuration, all of the V and J regions and intervening sequences from a human.
- the light chain VJ insert may comprise only the proximal clusters of V segments and J segments. Such an insert would be of approximately 473 kb.
- the human light chain kappa DNA such as the human IgK fragment of bases 88,940,356 to 89,857,000 from human chromosome 2 is suitably inserted into mouse chromosome 6 between coordinates 70,673,899 and 70,675,515, suitably at position 70,674,734.
- the human lambda VJ region comprises, in germline configuration, all of the V and J regions and intervening sequences from a human.
- this includes analogous bases to those selected for the kappa fragment, from human chromosome 2.
- All specific human fragments described above may vary in length, and may for example be longer or shorter than defined as above, such as 500 bases, 1 KB, 2K, 3K, 4K, 5KB, 10 KB, 20KB, 30KB, 40KB or 50KB or more, which suitably comprise all or part of the human V(D)J region, whilst preferably retaining the requirement for the final insert to comprise human genetic material encoding the complete heavy chain region and light chain region, as appropriate, as described above.
- the 5' end of the human insert described above is increased in length. Where the insert is generated in a stepwise fashion then the increase in length is generally in respect of the upstream (5') clone.
- the 3' end of the last inserted human gene generally the last human J gene to be inserted is less than 2kb, preferably less than 1 KB from the human-mouse join region.
- the non-human mammal comprises some or all of the human light chain kappa VJ region as disclosed herein but not the human light chain lambda VJ region.
- the genome comprises an insertion of V, D (heavy chain only) and J genes as described herein at the heavy chain locus and one light chain locus, or at the heavy chain locus and both light chain loci.
- the genome is homozygous at one, or both, or all three loci.
- the genome may be heterozygous at one or more of the loci, such as heterozygous for DNA encoding a chimaeric antibody chain and native (host cell) antibody chain.
- the genome may be heterozygous for DNA capable of encoding 2 different antibody chains of the invention, for example, comprising 2 different chimaeric heavy chains or 2 different chimaeric light chains.
- the invention relates to a non-human mammal or cell, and methods for producing said mammal or cell, as described herein, wherein the inserted human DNA, such as the human IgH VDJ region and/or light chain V, J regions are found on only one allele and not both alleles in the mammal or cell.
- a mammal or cell has the potential to express both an endogenous host antibody heavy or light chain and a chimaeric heavy or light chain.
- the human VDJ region, or light chain VJ region is not used in its entirety, but parts of the equivalent human VDJ or VJ region, such as the exons, from other species may be used, such as one or more V, D, or J exons from other species, or regulatory sequences from other species.
- the sequences used in place of the human sequences are not human or mouse.
- the sequences used may be from rodent, or, primate such as chimp.
- 1 , 2, 3, 4, or more, or all of the J regions from a primate other than a human may be used to replace, one, 2, 3, 4, or more or all of the human J exons in the VDJ/VJ region of the cells and animals of the invention.
- the inserted human DNA such as the human IgH VDJ region, and/or light chain VJ regions, may be inserted such that they are operably linked in the genome with a mu constant region from a non-human, non-mouse species, such as a rodent or primate sequence, such as a rat sequence.
- a non-human, non-mouse species such as a rodent or primate sequence, such as a rat sequence.
- Other non-human, non-mouse species from which DNA elements may be used in the present invention include rabbits, lamas, dromedary, alpacas, camels and sharks.
- the inserted human DNA such as the human VDJ or VJ region is not operably linked to the endogenous host mu sequence but rather to non-host mu sequence.
- Operable linkage suitably allows production of an antibody heavy or light chain comprising the human variable region.
- the inserted human DNA such as the human IgH VDJ region (and/or light chain VJ regions) may be inserted into the host chromosome together with mu constant region nucleic acid which is not host mu constant region nucleic acid, and preferably is a mu constant region from a non-mouse, non-human species.
- the inserted human DNA such as the human VDJ region (and/or light chain VJ regions) is operably linked to a non-human, non-mouse mu, and is able to form a chimaeric antibody heavy or light chain.
- non-mouse, non- human mu may be inserted into the host chromosome on a separate genetic element to that of the human variable region, or at a different location in the genome, suitably operably linked to the variable region such that a chimaeric antibody heavy or light can be formed.
- the invention relates to a cell, or non-human mammal, the genome of which comprises: one or more human Ig light chain kappa V regions and one or more human Ig light chain kappa J regions upstream of all or part of the human kappa constant region.
- the invention in another aspect relates to a cell, or non-human mammal, the genome of which comprises: one or more human Ig light chain lambda V regions and one or more human Ig light chain lambda J regions upstream of all or part of the human lambda constant region.
- the light chain VJ and C regions are able to form antibody chains in vivo capable of specifically reacting with an antigen.
- a human kappa and/or lambda region is inserted into the genome, in combination with insertion of the heavy chain VDJ region or part thereof, upstream of the host heavy chain constant region as disclosed herein.
- cell or non human mammal of the invention may comprise:
- non-human mammal is able to produce a repertoire of antibodies having an antibody chain comprising non human mammal constant region and a human variable region.
- the cell or non human mammal of the invention may comprise
- non-human mammal is able to produce a repertoire of antibodies having an antibody chain comprising a non-human mammal constant region and a human variable region.
- the insertion of the human VJC light chain DNA, or part thereof as disclosed above is made at the equivalent mouse locus.
- the human light chain kappa VJC DNA, or part thereof is inserted immediately upstream or downstream of the mouse kappa VJC region.
- the human light chain lambda VJC region or part thereof is inserted immediately upstream or downstream of the mouse lambda VJC region.
- only the human kappa VJC locus is inserted. Insertions may be made using the techniques disclosed herein, and suitably do not remove the host sequences from the genome.
- non human mammal host VJC sequences may be inactivated in some way, by mutation, or inversion, or by insertion of the human variable region DNA, or by any other means.
- the cell or non human mammal of the invention may comprise an insertion of the complete VJC human region.
- human kappa variable region DNA might be inserted into the genome in functional arrangement with a lambda constant region, for example inserted upstream of a lambda constant region.
- human lambda region variable DNA might be inserted in functional arrangement with a kappa constant region, for example inserted upstream of a kappa constant region.
- one or more non-human mammal control sequences such as the enhancer sequence(s) is maintained upstream of the nonhuman mammal Mu constant region, suitably in its native position with respect to the distance from the constant region.
- one or more non-human mammal control sequences such as an enhancer sequence(s) are maintained downstream of the nonhuman mammal Mu constant region, suitably in its native position with respect to the distance from the constant region.
- a non-human mammal switch sequence is maintained upstream of the non-human mammal Mu constant region, suitably in its native position with respect to distance from the constant region.
- the host enhancer or switch sequences are operative in vivo with the host constant region sequence(s).
- a switch sequence is neither human, nor native in the non-human mammal, for example in one aspect a non human mammal switch sequence is not a mouse or human switch sequence.
- the switch sequence may be, for example, a rodent or primate sequence, or a synthetic sequence.
- the switch sequence may be a rat sequence where the non human mammal is a mouse.
- a mouse or human constant mu sequence may be placed under the control of a switch sequence from a rat, or chimp, or other switch sequence, suitably capable of allowing isotype switching to occur in vivo.
- the cell or mammal of the invention may therefore comprise a human or non human mammal switch sequence and a human or non human mammal enhancer region or regions. They may be upstream of a human or non human mammal constant region.
- the control sequences are able to direct expression or otherwise control the production of antibodies comprising a constant region with which they are associated.
- One combination envisaged is a rat switch with mouse enhancer sequences and mouse constant regions in a mouse cell.
- the invention relates to a cell, preferably a non human cell, or non human mammal comprising an immunoglobulin heavy chain or light chain locus having DNA from 3 or more species.
- the cell or animal may comprise host cell constant region DNA, one or more human V, D or J coding sequences and one or more non-human, non-host DNA regions that are able to control a region of the immunoglobulin locus, such as a switch sequence, promoter or enhancer which are able to control expression or isotype switching in vivo of the Ig DNA.
- the cell or animal is a mouse and comprises additionally human DNA from the human Ig locus and additionally a non-mouse DNA sequence, such as a rat DNA sequence, capable of regulation of the mouse or human DNA.
- the invention in another aspect relates to a cell, preferably non-human cell, or non-human mammal comprising an immunoglobulin heavy chain or light chain locus having DNA from 2 or more different human genomes.
- a cell preferably non-human cell, or non-human mammal comprising an immunoglobulin heavy chain or light chain locus having DNA from 2 or more different human genomes.
- it could comprise heavy chain V(D)J sequences from more than one human genome within a heavy or light chain, or heavy chain VDJ DNA from one genome and light chain VJ sequences from a different genome.
- the invention relates to a DNA fragment or cell or non-human mammal comprising an immunoglobulin heavy chain or light chain locus, or part thereof, having DNA from 2 or more species, where one species contributes a non coding region such as a regulatory region, and the other species coding regions such as V, D, J or constant regions.
- the human promoter and/or other control elements that are associated with the different human V, D or J regions are maintained in the mouse genome.
- one or more of the promoter elements, or other control elements, of the human regions, such as the human V regions, are optimised to interact with the transcriptional machinery of a non-human mammal.
- a human coding sequence may be placed under the control of an appropriate non- human mammal promoter, which allows the human DNA to be transcribed efficiently in the appropriate non-human animal cell.
- the human region is a human V region coding sequence, and a human V region is placed under the control of a non-human mammal promoter.
- the functional replacement of human promoter or other control regions by non-human mammal promoter or control regions may be carried out by use of recombineering, or other recombinant DNA technologies, to insert a part of the human Ig region (such as a human V region) into a vector (such as a BAC) containing a non-human Ig region.
- the recombineering/recombinant technique suitably replaces a portion of the non-human (e.g. mouse) DNA with the human Ig region, and thus places the human Ig region under control of the non-human mammal promoter or other control region.
- the human coding region for a human V region replaces a mouse V region coding sequence.
- the human coding region for a human D region replaces a mouse D region coding sequence.
- the human coding region for a human J region replaces a mouse J region coding sequence.
- human V, D or J regions may be placed under the control of a non-human mammal promoter, such as a mouse promoter.
- the only human DNA inserted into the non-human mammalian cell or animal are V, D or J coding regions, and these are placed under control of the host regulatory sequences or other (non-human, non-host) sequences,
- reference to human coding regions includes both human introns and exons, or in another aspect simply exons and no introns, which may be in the form of cDNA.
- recombineering or other recombinant DNA technologies, to insert a non human-mammal (e.g. mouse) promoter or other control region, such as a promoter for a V region, into a BAC containing a human Ig region.
- a non human-mammal e.g. mouse
- the recombineering step then places a portion of human DNA under control of the mouse promoter or other control region.
- V, D and J regions may also be used to insert some or all of the V, D and J regions from the human heavy chain upstream of a light chain constant region, rather than upstream of the heavy chain constant region.
- some or all of the human light chain V and J regions may be inserted upstream of the heavy chain constant region. Insertion may be at the endogenous constant region locus, for example between the endogenous constant and J region, and may be of some, or all, of the V, D or J genes alone, excluding promoter or enhancer sequences, or may be of some, or all, of the V, D or J genes with one or more or all respective promoter or enhancer sequences.
- the full repertoire of V, D or J fragments in germline orientation may be inserted upstream and in functional arrangement with a host constant region.
- the present invention allows V and/or D and/or J regions from a human, or any species, to be inserted into a chromosome of a cell from a different species that comprises a constant region, allowing a chimaeric antibody chain to be expressed.
- the invention requires only that some human variable region DNA is inserted into the genome of a non human mammal in operable arrangement with some, or all, of the human heavy chain constant region at the region of the endogenous heavy chain constant region locus such that an antibody chain can be produced.
- the light chain DNA insertion can be in the form of a completely human construct, having both human variable DNA and human constant region DNA, or have human variable region DNA and constant region DNA from a non-human, non-host species.
- Other variations are also possible, such as insertion of both of the light chain human variable region and host genome constant region.
- the insertion of said light chain transgenes need not be at the equivalent endogenous locus, but may be anywhere in the genome.
- the cell or mammal may produce chimaeric heavy chains (comprising human variable region DNA and mouse constant region DNA) and light chains comprising human variable and human constant region DNA.
- the lambda and or kappa human variable region DNA can be inserted upstream of the endogenous locus, or downstream, or indeed on a different chromosome to the endogenous locus, and inserted with or without constant region DNA.
- a further aspect of the invention relates to insertion of one or both light chain human variable regions downstream of the endogenous locus constant region, or elsewhere in the genome.
- insertion of human variable region DNA at or close to the equivalent endogenous locus in the recipient genome is preferred, for example within 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10kb of the boundary (upstream or downstream) of a host immunoglobulin locus.
- the invention can relate to a cell or non-human mammal whose genome comprises:
- the genome of the cell or non human mammal comprises: a plurality of human IgH V regions, one or more human D regions and one or more human J regions upstream of the host non-human mammal constant region; one or more human Ig light chain kappa V regions and one or more human Ig light chain kappa J regions upstream of the host non-human mammal kappa constant region, and one or more human Ig light chain lambda V regions and one or more human Ig light chain lambda J regions downstream of the host non-human mammal lambda constant region, optionally in which the human lambda variable region may be inserted downstream of the endogenous host lambda locus in operable linkage with a human lambda constant region, such that the non human mammal or cell can produce fully human antibody light chains and chimaeric heavy chains.
- the use of the methods of the invention allows a locus to be built up in a stepwise manner by sequential insertions, and thus allows for the insertion of human variable DNA together with human or non human constant region DNA at any suitable location in the genome of a non-human host cell.
- methods of the invention can be used to insert human immunoglobulin variable region DNA together with constant region DNA from the host genome anywhere in the genome of a non-human host cell, allowing a chimaeric antibody chain to be produced from a site other than the endogenous heavy region.
- Any human heavy chain or light chain DNA construct contemplated above can be inserted into any desired position into the genome of a non human host cell using the techniques described herein.
- the present invention thus also relates to cells and mammals having genomes comprising such insertions.
- the invention also relates to a vector, such as a BAC, comprising a human V, D or J region in a functional arrangement with a non-human mammal promoter, or other control sequence, such that the expression of the human V, D or J region is under the control of the non-human mammal promoter in a cell of the non-human mammal, such as an ES cell, in particular once inserted into the genome of that cell.
- a vector such as a BAC, comprising a human V, D or J region in a functional arrangement with a non-human mammal promoter, or other control sequence, such that the expression of the human V, D or J region is under the control of the non-human mammal promoter in a cell of the non-human mammal, such as an ES cell, in particular once inserted into the genome of that cell.
- the invention also relates to cells and non-human mammals containing said cells, which cells or mammals have a human V, D or J region in a functional arrangement with a non-human mammal promoter, or other control sequence, such that the expression of the human V, D or J region is under the control of the non-human mammal promoter in the cells or mammal.
- one aspect of the invention thus relates to a non human mammal host cell capable of expression of a human V, D or J coding sequence under the control of a host promoter or control region, the expression capable of producing a humanised antibody having a human variable domain and non human mammal constant region.
- the invention relates to a cell, such as a non mammalian cell, such as an ES cell, the genome of which comprises a) a plurality of human IgH V regions, one or more human D regions and one or more human J regions upstream of the host non-human mammal constant region; and
- the invention relates to a cell, such as a non-human mammal cells, such as ES cells whose genome comprises
- the cell is an ES cell is capable of developing into a non-human mammal able to produce a repertoire of antibodies which are chimaeric, said chimaeric antibodies having a non- human mammal constant region and a human variable region.
- the genome of the cell is modified to prevent expression of fully host-species specific antibodies.
- the cell is an induced pluripotent stem cell (iPS cell).
- iPS cell induced pluripotent stem cell
- cells are isolated non human mammalian cells.
- a cell as disclosed herein is preferably a non human mammalian cell.
- the invention also relates to a cell line which is grown from or otherwise derived from cells as described herein, including an immortalised cell line.
- the cell line may comprise inserted human V, D or J genes as described herein, either in germline configuration or after rearrangement following in vivo maturation.
- the cell may be immortalised by fusion to a tumour cell to provide an antibody producing cell and cell line, or be made by direct cellular immortalisation.
- the present invention also relates to vectors for use in the invention.
- vectors for use in the invention.
- such vectors are BACs (bacterial artificial chromosomes). It will be appreciated that other cloning vectors may be used in the invention, and therefore reference to BACs herein may be taken to refer generally to any suitable vector.
- BACs used for generation of human DNA to be inserted such as the VDJ or VJ regions, are trimmed, so that in the final human VDJ or VJ region, or part thereof, in the non- human mammal no sequence is duplicated or lost when compared to the original human genomic sequence.
- the invention relates to a vector comprising an insert, preferably comprising a region of human DNA from some of the human VDJ or VJ locus, flanked by DNA which is not from that locus.
- the flanking DNA may comprise one or more selectable markers or one or more site specific recombination sites.
- the vector comprises 2 or more, such as 3, heterospecific and incompatible site specific recombination sites.
- the site specific recombination sites may be loxP sites, or variants thereof, or FRT sites or variants thereof.
- the vector comprises one or more transposon ITR (inverted terminal repeat) sequences.
- non-human animals of the invention suitably do not produce any fully humanised antibodies. In one aspect this is because there is no DNA inserted from the human constant region. Alternatively there is no human constant region DNA in the genome capable of forming an antibody in conjunction with the inserted human variable region DNA component, for example due to mutation within any human constant region DNA or distance from any constant region human DNA and human variable region DNA.
- human light chain constant region DNA may be included in the cell genome, such that a fully human lambda or kappa human antibody chain might be generated, but this would only be able to form an antibody with a chimaeric heavy chain, and not produce a fully human antibody having human variable and constant regions.
- the non-human mammal genome is modified to prevent expression of fully host- species specific antibodies.
- Fully host species specific antibodies are antibodies that have both variable and constant regions from the host organism.
- 'specific' is not intended to relate to the binding of the antibodies produced by the cells or animals of the invention but rather to the origin of the DNA which encodes those antibodies.
- the non-human mammal genome is modified to prevent expression of the native (fully host species specific) antibodies in the mammal by inactivation of all or a part of the host non-human mammal Ig loci. In one aspect this is achieved by inversion of all or part of the non- human mammal VDJ region, or VJ region, optionally by insertion of one or more site specific recombinase sites into the genome and then use of these sites in recombinase-mediated excision or inversion of all or a part of the non-human mammal Ig locus.
- a double inversion may be employed, the first to move the V(D)Js away from the endogenous locus and then a more local inversion which puts them in the correct orientation.
- a single loxP site is used to invert the non-human mammal VDJ region to a centromeric locus or telomeric locus.
- non human mammal genome into which human DNA is inserted comprises endogenous V, (D) and J regions, and the endogenous sequences have not been deleted.
- the invention comprises a method for insertion of multiple DNA fragments into a DNA target, suitably to form a contiguous insertion in which the inserted fragments are joined together directly without intervening sequences.
- the method is especially applicable to the insertion of a large DNA fragment into a host chromosome which can be carried out in a stepwise fashion.
- the method comprises insertion of a first DNA sequence into a target, the sequence having a DNA vector portion and a first sequence of interest (X1 ); insertion of a second DNA sequence into the vector portion of the first sequence, the second DNA sequence having a second sequence of interest (X2) and a second vector portion; and then excising any vector sequence DNA separating X1 and X2 to provide a contiguous X1X2, or X2X1 sequence within the target.
- the DNA target for insertion of the first DNA sequence may be a specific site or any point in the genome of a particular cell.
- the general method is described herein in relation to the insertion of elements of the human VDJ region, but is applicable to insertion of any DNA region, from any organism, and in particular insertion of large DNA fragments of > 10OkB, such as 100 - 250kb, or even larger, such as that of the TCR or HLA.
- Features and approaches described herein in respect of the VDJ insertion may be equally applied to the any of the methods disclosed
- the inserted DNA is human DNA, such as the human VDJ or VJ region, is built up in the genome of a cell, such as an ES cell, in a stepwise manner using 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 20 or more separate insertions for each heavy chain or light chain region. Fragments are suitably inserted at the same or substantially the same cell locus, e.g. ES cell locus, one after another, to form the complete VDJ or VJ region, or part thereof.
- the present invention also relates to cells and non-human animals comprising intermediates in the process whose genomes may comprise only a partial VDJ region, such as only human variable region DNA.
- the method for producing a transgenic non-human mammal comprises the insertion of human VDJ or VJ regions upstream of the host non-human mammal constant region by step-wise insertion of multiple fragments by homologous recombination, preferably using an iterative process.
- fragments of approximately 100KB from the human VDJ and VJ locus are inserted, suitably to form part of, or a complete, VDJ or VJ region after the final iteration of the insertion process, as disclosed herein.
- the insertion process commences at a site where an initiation cassette has been inserted into the genome of a cell, such as an ES cell, providing a unique targeting region.
- the initiation cassette is inserted in the non human mammal heavy chain locus, for use in insertion of human heavy chain DNA.
- an initiation cassette is inserted in the non human mammal light chain locus, for use in insertion of human light chain VJ DNA
- the initiation cassette suitably comprises a vector backbone sequence with which a vector having a human DNA fragment in the same backbone sequence can recombine to insert the human DNA into the cell (e.g. ES) cell genome, and suitably a selection marker, such as a negative selection marker.
- the vector backbone sequence is that of a BAC library, to allow BACs to be used in the construction of the ES cells and mammals.
- the vector backbone sequence may however be any sequence which serves as a target site into which a homologous sequence can insert, for example by homologous recombination and RMCE, and is preferably not DNA encoding any of the VDJ or constant region.
- the insertion of the first DNA fragment into an initiation cassette is followed by insertion of a second DNA fragment into a portion of the first DNA fragment, suitably a part of the vector backbone of the second DNA fragment.
- an inserted DNA fragment comprises a part of the human VDJ region flanked by 5' and/or 3' sequences that are not from the human VDJ region.
- the 5' and/or 3' flanking sequences may each contain one or more selectable markers, or be capable of creating a selectable system once inserted into the genome.
- one or both flanking sequences may be removed from the genome in vitro, or in vivo, following insertion.
- the method comprises insertion of a DNA fragment followed by selection of both 5' and 3' ends of the inserted fragment flanking the human VDJ DNA.
- iterative insertion is made by insertion of DNA fragments at the 5' end of the previous inserted fragment, and in this aspect there may be deletion in vivo of the vector DNA which separates the inserted human DNA sequences, to provide a contiguous human DNA sequence.
- insertion of human VDJ DNA into a genome may be achieved without leaving any flanking DNA in the genome, for example by transposase mediate DNA excision.
- transposase is the Piggybac transposase.
- the first human variable region fragment is inserted by homologous recombination at the initiation cassette backbone sequence and then the DNA of any negative selection marker and initiation cassette are subsequently removed by recombination between recombinase target sequences, such as FRT using in this example, FLPase expression.
- recombinase target sequences such as FRT using in this example, FLPase expression.
- targeted insertions at the (e.g. BAC) backbone initiation sequence and subsequent removal by rearrangement between recombinase target sequences are repeated to build up the entire human VDJ region upstream of the host non-mammal constant region.
- a selectable marker or system may be used in the method.
- the marker may be generated upon insertion of a DNA fragment into a genome, for example forming a selectable marker in conjunction with a DNA element already present in the genome.
- the cell (e.g. ES) cell genome does not contain 2 identical selectable markers at the same time during the process. It can be seen that the iterative process of insertion and selection can be carried out using only 2 different selection markers, as disclosed in the examples herein, and for example the third selectable marker may be identical to the first marker, as by the time of insertion of the third vector fragment the first vector fragment and the first marker has been removed.
- a correct insertion event is confirmed before moving to the next step of any multistep cloning process, for example by confirmation of BAC structure using high density genomic arrays to screen ES cells to identify those with intact BAC insertions, sequencing and PCR verification.
- the method uses site specific recombination for insertion of one or more vectors into the genome of a cell, such as an ES cell.
- Site specific recombinase systems are well known in the art and may include Cre-lox, and FLP/FRT or combinations thereof, in which recombination occurs between 2 sites having sequence homology.
- Suitable BACs are available form the Sanger centre, see "A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction". Adams DJ, Quail MA, Cox T, van der Weyden L, Gorick BD, Su Q, Chan Wl, Davies R, Bonfield JK, Law F, Humphray S, Plumb B, Liu P, Rogers J, Bradley A. Genomics. 2005 Dec;86(6):753-8. Epub 2005 Oct 27. The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1 SA, UK. BACs containing human DNA are also available from, for example, Invitrogen. A suitable library is described in Osoegawa K et a/, Genome Research 2001. 11 : 483-496.
- a method of the invention specifically comprises:
- the invention comprises
- the first DNA fragment comprising a first portion of a human DNA and a first vector portion containing a first selectable marker or generating a selectable marker upon insertion;
- the non-human mammal is able to generate a diversity of at least 1 X 10 6 different functional chimaeric immunoglobulin sequence combinations.
- the targeting is carried out in ES cells derived from the mouse C57BL/6N, C57BL/6J, 129S5 or 129Sv strain.
- non-human animals such as mice are generated in a RAG-1 -deficient background, or other suitable genetic background which prevents the production of mature host B and T lymphocytes.
- non-human mammal is a rodent, suitably a mouse
- cells of the invention are rodent cells or ES cells, suitably mouse ES cells.
- the ES cells of the present invention can be used to generate animals using techniques well known in the art, which comprise injection of the ES cell into a blastocyst followed by implantation of chimaeric blastocystys into females to produce offspring which can be bred and selected for homozygous recombinants having the required insertion.
- the invention relates to a chimeric animal comprised of ES cell-derived tissue and host embryo derived tissue.
- the invention relates to genetically-altered subsequent generation animals, which include animals having a homozygous recombinants for the VDJ and/or VJ regions.
- the invention relates to a method for producing an antibody specific to a desired antigen the method comprising immunizing a transgenic non-human mammal as above with the desired antigen and recovering the antibody (see e.g. Harlow, E. & Lane, D. 1998, 5 th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY; and Pasqualini and Arap, Proceedings of the National Academy of Sciences (2004) 101 :257-259).
- an immunogenic amount of the antigen is delivered.
- the invention also relates to a method for detecting a target antigen comprising detecting an antibody produced as above with a secondary detection agent which recognises a portion of that antibody.
- the invention relates to a method for producing a fully humanised antibody comprising immunizing a transgenic non-human mammal as above with the desired antigen, recovering the antibody or cells expressing the antibody, and then replacing the non-human mammal constant region with a human constant region.
- This can be done by standard cloning techniques at the DNA level to replace the non-human mammal constant region with an appropriate human constant region DNA sequence - see e.g. Sambrook, J and Russell, D. (2001 , 3'd edition) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press, Plainview, NY).
- the invention relates to humanised antibodies and antibody chains produced according to the present invention, both in chimaeric and fully humanised form, and use of said antibodies in medicine.
- the invention also relates to a pharmaceutical composition comprising such an antibodies and a pharmaceutically acceptable carrier or other excipient.
- Antibody chains containing human sequences such as chimaeric human-non human antibody chains, are considered humanised herein by virtue of the presence of the human protein coding regions region.
- Fully humanised antibodies may be produced starting from DNA encoding a chimaeric antibody chain of the invention using standard techniques.
- chimaeric antibodies or antibody chains generated in the present invention may be manipulated, suitably at the DNA level, to generate molecules with antibody-like properties or structure, such as a human variable region from a heavy or light chain absent a constant region, for example a domain antibody; or a human variable region with any constant region from either heavy or light chain from the same or different species; or a human variable region with a non-naturally occurring constant region; or human variable region together with any other fusion partner.
- the invention relates to all such chimaeric antibody derivatives derived from chimaeric antibodies identified according to the present invention.
- the invention relates to use of animals of the present invention in the analysis of the likely effects of drugs and vaccines in the context of a quasi-human antibody repertoire.
- the invention also relates to a method for identification or validation of a drug or vaccine, the method comprising delivering the vaccine or drug to a mammal of the invention and monitoring one or more of: the immune response, the safety profile; the effect on disease.
- the invention also relates to a kit comprising an antibody or antibody derivative as disclosed herein and either instructions for use of such antibody or a suitable laboratory reagent, such as a buffer, antibody detection reagent.
- a suitable laboratory reagent such as a buffer, antibody detection reagent.
- the invention relates to:
- a non-human mammal whose genome comprises:
- a non-human mammal ES cell whose genome comprises:
- a method for producing a transgenic non-human mammal able to produce a repertoire of chimaeric antibodies, the antibodies having a non-human mammal constant region and a human variable region comprising inserting by homologous recombination into a non-human mammal ES cell genome
- steps (a) and (b) can be carried out in either order and each of steps (a) and (b) can be carried out in a stepwise manner or as a single step.
- the insertion of human VDJ or VJ regions upstream of the host non-human mammal constant region is accomplished by step-wise insertion of multiple fragments by homologous recombination.
- the step-wise insertions commence at a site where an initiation cassette has been inserted into the genome of an ES cell providing a unique targeting region consisting of a BAC backbone sequence and a negative selection marker.
- the first human variable region fragment is inserted by homologous recombination at the initiation cassette BAC backbone sequence and said negative selection marker and initiation cassette are subsequently removed by recombination between recombinase target sequences.
- repeated targeted insertions at the BAC backbone initiation sequence and subsequent removal of the backbone by rearrangement between recombinase target sequences is repeated to build up the entire human VDJ region upstream of the host non-mammal constant region.
- a method for producing an antibody specific to a desired antigen comprising immunizing a non-human mammal as disclosed herein with the desired antigen and recovering the antibody or a cell producing the antibody.
- a method for producing a fully humanised antibody comprising immunizing a non-human mammal as disclosed herein and then replacing the non-human mammal constant region of an antibody specifically reactive with the antigen with a human constant region, suitably by engineering of the nucleic acid encoding the antibody.
- the human coding region V, D or J region is in a functional arrangement with a mouse promoter sequence.
- the invention also relates to a humanised antibody produced according to any methods disclosed herein and use of a humanised antibody so produced in medicine.
- the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), "including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps
- compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- Example 3 discloses experimental data that has been obtained which supports the proof of concept of certain aspects of the invention, while Example 1 and 2 provide detailed guidance for the person skilled in the art in carrying out the claimed invention.
- a mouse model of the invention can be achieved by inserting ⁇ 960kb of the human heavy chain locus containing all the V, D and J-regions upstream of the mouse constant region and 473kb of the human kappa region upstream of the mouse constant region.
- the human lambda region is inserted upstream of the mouse constant region. This insertion is achieved by gene targeting in ES cells using techniques well known in the art.
- High fidelity insertion of intact V-D-J regions into each locus in their native (wild-type) configuration is suitably achieved by insertion of human bacterial artificial chromosomes (BACs) into the locus.
- BACs human bacterial artificial chromosomes
- the BACs are trimmed so that in the final locus no sequence is duplicated or lost compared to the original. Such trimming can be carried out by recombineering.
- the relevant human BACs, suitably trimmed covering these loci are on average 90kb in size.
- the first BACs to be inserted in the IgH and IgK loci may contain the following V-regions. IgH ⁇ /6-1 , VII-1-1 , V1-2, VIII-2-1 , V1-3, V4-4, V2-5 and IgK: V4-1 , V5-2, V7- 3, V2-4, V1-5, V1-6, V3-7, V1-8.
- each locus is assessed after the first BAC insertion using chimaeric mice and also after each subsequent BAC addition. See below for detailed description of this performance test.
- Nine additional BAC insertions will be required for the IgH locus and five for IgK to provide the full complement of human V-regions covering all 0.96Mb and 0.473Mb of the IgH and IgK loci, respectively.
- BACs retain their wild-type configuration when inserted into the ES cell genome.
- high density genomic arrays to screen ES cells to identify those with intact BAC insertions (Barrett, MT. , Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer, P. S., et al. (2004). Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proceedings of the National Academy of Sciences of the United States of America 101, 17765-17770. ).
- This screen also enables one to identify and select against ES clones in which the ES cell genome is compromised and thus not able to populate the germ line of chimeric animals.
- Other suitable genomic tools to facilitate this assessment include sequencing and PCR verification.
- the correct BAC structure is confirmed before moving to the next step.
- the cell lines currently in use for the KOMP and EUCOMM global knockout projects have been modified twice prior to their use for this project and their germ line transmission rates are unchanged from the parental cells (these lines are publicly available, see www.komp.org and www.eucomm.org).
- This cell line, called JM8 can generate 100% ES cell- derived mice under published culture conditions (Pettitt, S. J., Liang, Q., Rairdan, X.Y., Moran, J. L., Prosser, H. M., Beier, D.
- the ability to generate chimeras with such high percentage of ES cell-derived tissue has other advantages.
- HPRT-ve cell line such as AB2.1
- AB2.1 HPRT-ve cell line
- mice While many clones will generate 100% ES derived mice some will not. Thus, at every step mice are generated in a RAG-1 -deficient background. This provides mice with 100% ES-derived B- and T-cells which can be used directly for immunization and antibody production. Cells having a RAG-2 deficient background, or a combined RAG-1/RAG-2 deficient background may be used, or equivalent mutations in which mice produce only ES cell-derived B cells and/or T cells.
- the human-mouse IgH and IgK loci can be engineered in a cell line in which one allele of the IgH or IgK locus has already been inactivated.
- the inactivation of the host Ig locus, such as the IgH or IgK locus can be carried out after insertion.
- mice that have the RAG-1 gene mutated are immunodeficient as they have no mature B- or T-lymphocytes (US 5,859,307). T- and B-lymphocytes only differentiate if proper V(D)J recombination occurs. Since RAG-1 is an enzyme that is crucial for this recombination, mice lacking RAG-1 are immunodeficient. If host embryos are genetically RAG-1 homozygous mutant, a chimera produced by injecting such an embryo will not be able to produce antibodies if the animal's lymphoid tissues are derived from the host embryo.
- JM8 cells and AB2.1 cells generally contribute in excess of 80% of the somatic tissues of the chimeric animal and would therefore usually populate the lymphoid tissue.
- JM8 cells have wild-type RAG-1 activity and therefore antibodies produced in the chimeric animal would be encoded by the engineered JM8 ES cell genome only. Therefore, the chimeric animal can be challenged with an antigen by immunization and subsequently produce antibodies to that antigen. This allows one skilled in the art to test the performance of the engineered human/mouse IgH and IgK loci as described in the present invention. See figures 19 and 20.
- chimeric animal as described to determine the extent of antibody diversity (see e.g. Harlow, E. & Lane, D. 1998, 5 th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY).
- the existence in the chimeric animal's serum of certain antibody epitopes could be ascertained by binding to specific anti-idiotype antiserum, for example, in an ELISA assay.
- One skilled in the art could also sequence the genomes of B-cell clones derived from the chimeric animal and compare said sequence to wild-type sequence to ascertain the level of hypermutation, such hypermutation indicative of normal antibody maturation.
- chimeric animal would also use said chimeric animal to examine antibody function wherein said antibodies are encoded from the engineered Ig loci (see e.g. Harlow, E. & Lane, D. 1998, 5 th edition, Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, NY).
- antisera could be tested for binding an antigen, said antigen used to immunize the chimeric animal. Such a measurement could be made by an ELISA assay.
- one skilled in the art could test for neutralization of the antigen by addition of the antisera collected from the appropriately immunized chimeric animal.
- Recombineering for the production of vectors for use in homologous recombination in ES cells is disclosed in, for example, WO9929837 and WO0104288, and the techniques are well known in the art.
- the recombineering of the human DNA takes place using BACs as a source of said human DNA.
- Human BAC DNA will be isolated using Qiagen BAC purification kit.
- the backbone of each human BAC will be modified using recombineering to the exact same or similar configuration as the BAC already inserted into the mouse IgH region.
- each human BAC will be trimmed using recombineering so that once the BACs are inserted, a seamless contiguous part of the human V(D)J genomic region will form at the mouse IgH or IgK locus.
- BAC DNA transfection by electroporation and genotyping will be performed accordingly to standard protocols (Prosser, H. M., Rzadzinska, A.K., Steel, K.P., and Bradley, A. (2008).
- Mosaic complementation demonstrates a regulatory role for myosin Vila in actin dynamics of stereocilia. Molecular and Cellular Biology 28, 1702-1712; Ramirez-Solis, R., Davis, A.C., and Bradley, A. (1993). Gene targeting in embryonic stem cells.
- C57BL/6N-derived cell lines such as the JM8 male ES cells will follow standard techniques.
- the JM8 ES cells have been shown to be competent in extensively contributing to somatic tissues and to the germline, and are being used for large mouse mutagenesis programs at the Sanger Institute such as EUCOMM and KOMP (Pettitt, S.J., Liang, Q., Rairdan, X.Y., Moran, J. L., Prosser, H. M., Beier, D. R., Lloyd, K.C., Bradley, A., and Skarnes, W.C. (2009). Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nature Methods.).
- JM8 ES cells (1.0X10 7 ) will be electroporated (500 ⁇ F, 230V; BioRad) with 10 ⁇ g I-Scel linearized human BAC DNA.
- the transfectants will be selected with either Puromycin (3 ⁇ g/ml) or G418 (150 ⁇ g/ml). The selection will begin either 24 hours (with G418) or 48 hours (with Puromycin) post electroporation and proceed for 5 days.
- 10 ⁇ g linearized human BAC DNA can yield up to 500 Puromycin or G418 resistant ES cell colonies. The antibiotic resistant ES cell colonies will be picked into 96-well cell culture plates for genotyping to identify the targeted clones.
- BAC integrity will be examined by PCR-amplifying each known functional V gene in the BAC.
- the first human BAC chosen for the IgH locus has 6 functional V genes.
- at least 14 pairs of PCR primers will be designed and used to PCR-amplify genomic DNA from the targeted ES cells. The human wild-type size and sequence of these fragments will ensure that the inserted BAC has not been rearranged.
- More detailed CGH will also confirm the integrity of the inserted BACs.
- an oligo aCGH platform which is developed by Agilent Technologies, Inc. This platform not only enables one to study genome-wide DNA copy number variation at high resolution (Barrett, MT. , Scheffer, A., Ben-Dor, A., Sampas, N., Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer, P. S., et al. (2004). Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA.
- the 60-mer oligonucleotides probes can ensure specific hybridization and high sensitivity and precision that is needed in order to detect the engineered chromosome alterations that we have made. For example, oligos designed to hybridize at regular intervals along the entire length of the inserted BAC would detect even quite short deletions, insertions or other rearrangements. Also, this platform provides the greatest flexibility for customized microarray designs.
- the targeted ES cell genomic DNA and normal human individual genomic DNA will be labelled separately with dyes and hybridized to the array.
- Log2 ratio between -0.29 and +0.29 for the signal from any oligo probe are regarded as no copy number change.
- the Iog2 ratio threshold for "Duplication" is usually >0.29999, and for deletion is ⁇ 0.29999.
- the FRT-flanked BAC backbone will be excised by using FIp site-specific recombinase. If regular Flp-catalyzed FRT recombination is not high enough, one can use Flo, an improved version of Flpo recombinase which in certain tests is 3-4 times more efficient than the original FIp in ES cells.
- ES cells will become sensitive to Puromycin (or G418) and resistant to FIAU (for loss of the TK cassette). The excision events will be further characterized by PCR amplification of the junction fragment using human genomic DNA primers.
- Targeting of the genome of an ES cell to produce a transgenic mouse may be carried out using a protocol as explained by reference to the attached figures 1- 18.
- Figure 1 illustrates three basic backbone vectors; an initiating cassette and 2 large insert vectors 1 and 2 respectively.
- the initiating cassette comprises sequences homologous to the desired site of insertion into the mouse genome, those sites flanking a selectable marker and stuffer primer sequence for PCR based genotyping to confirm correct insertion of BACs.
- the Stuffer- primer sequence provides the basis for genotyping each BAC addition step. This sequence is considered to provide a robust well validated sequence template for PCR primer and may be located at the IScel site, ideally ⁇ 1 kb from the BAC insert.
- the large insert vectors comprise human DNA on plasmids with selectable markers and a unique restriction site for linearisation of the plasmid to aid in homologous recombination into the genome of the ES cell.
- Figure 2 illustrates insertion of an initiating cassette into the mouse genome by Homologous recombination between the mouse J4 and C alpha exons.
- Puromycin selection allows identification of ES cells with insertion of the cassette.
- pu(Delta)tk is a bifunctional fusion protein between puromycin N-acetyltransferase (Puro) and a truncated version of herpes simplex virus type 1 thymidine kinase (DeltaTk).
- Murine embryonic stem (ES) cells transfected with pu(Delta)tk become resistant to puromycin and sensitive to 1-(-2-deoxy-2-fluoro-1-beta-D-arabino-furanosyl)- 5-iodouracil (FIAU).
- puDeltatk is readily transmitted through the male germ line.
- pu(Delta)tk is a convenient positive/negative selectable marker that can be widely used in many ES cell applications.
- Figure 3 illustrates targeting of the large insert vector 1 to the mouse ES cell genome.
- Linearisation of the vector is made at the same position as the stuffer primer sequence which allows for a gap repair genotyping strategy, well known in the art - see Zheng et al NAR 1999, VoI 27, 11 , 2354 - 2360.
- a gap repair genotyping strategy well known in the art - see Zheng et al NAR 1999, VoI 27, 11 , 2354 - 2360.
- Juxtaposition of appropriate PCR primer sequences allows colonies to be screened individually for a positive PCR fragment indicating proper insertion.
- Positive selection using G418 allows for identification of mouse ES cells containing the neo selection marker.
- PCR verification can be made of all critical V, D and J regions.
- Array comparative genomic hybridization can be used to validate the BAC structure.
- Figure 4 illustrates the puro-delta-tk cassette and the BAC plasmid backbone is deleted using Flpe and select in FIAU. Since Flpe works inefficiently in mouse ES cells (5% deletion with transient Flpe expression), it is expected that in most cases, the recombination occurs between the two FRT sites flanking the BAC backbone. Flpo can also be tested to find out the recombination efficiency between two FRT sites that are 10kb away.
- Figure 5 illustrates a second large insert vector is targeted into the ES cell chromosome.
- the human BAC is targeted to the mouse IgH locus using the same initiation cassette insertion followed by IScei BAC linearization, BAC targeting to the initiation cassette and gap-repair genotyping strategy. Verification of the BAC insertion is carried out as before.
- Figure 6 illustrates the FRTY flanked BAC backbone of large insert vector 2 and the neo marker are deleted via Flpo. Note that this is not selectable, thus it will be necessary for clonal analysis at this point. This will enable confirmation of the juxtaposition of the human 2 insert with human 1 and other validation efforts.
- Figure 7 illustrates the next large insert vector targeted to the mouse IgH locus.
- the pu-delta TK cassette is then removed, as for figure 4.
- the process can be repeated to incorporate other BACs.
- Figure 8 illustrates the final predicted ES cell construct.
- Figures 9 - 18 provide a further level of detail of this process.
- Example 2 In a further method of the invention site specific recombination can also be employed.
- Site- specific recombination has been widely used in the last 20-years for the integration of transgenes into defined chromosomal loci. SSR involves recombination between homologous DNA sequences.
- the first generation of SSR-based chromosomal targeting involved recombination between (i) a single recombination target site (RT) such as loxP or FRT in a transfected plasmid with (ii) a chromosomal RT site provided by a previous integration.
- RT recombination target site
- RMCE recombinase-mediated cassette exchange
- Biochemistry 33: 12746-12751 Their method is based on using two heterospecific and incompatible RTs in the transfected plasmid which can recombine with compatible RT sites on the chromosome resulting in the swap of one piece of DNA for another - or a cassette exchange.
- This approach has been successfully exploited in a variety of efficient chromosomal targeting, including integration of BAC inserts of greater than 50 kb (Wallace, H.A.C. et al. (2007). "Manipulating the mouse genome to engineering precise functional syntenic replacements with human sequence". Cell 128: 197-209; Prosser, H. M. et al. (2008). "Mosaic complementation demonstrates a regulatory role for myosin Vila in actin dynamics of Stereocilia”. MoI. Cell. Biol. 28: 1702-12).
- the largest insert size of a BAC is about 300-kb and therefore this places an upper limit on cassette size for RMCE.
- SRMCE sequential RMCE
- the method comprises the steps of
- the first DNA fragment comprising a first portion of a human DNA and a first vector portion containing a first selectable marker or generating a selectable marker upon insertion;
- the approach utilizes three heterospecific and incompatible loxP sites.
- the method is comprised of the steps as follows, and illustrated in Figures 22 - 26:
- An entry vector containing an HPRT mini- gene flanked by inverted piggyBac (PB) ITRs is targeted into defined region (for example: a region between IGHJ and E ⁇ or IGKJ and EK or IGLC1 and EA3-1 ) to serve as a landing pad for BAC targeting.
- the HPRT mini-gene is comprised of two synthetic exons and associated intron.
- the 5' HPRT exon is flanked by two heterospecific and incompatible loxP sites (one wild-type and the other a mutated site, Iox5171 ) in inverted orientation to each other (Fig. 22). These two loxP sites provide recombination sites for the BAC insertion through RMCE.
- the 1 st modified BAC has a length of DNA to be inserted into the genome flanked by engineered modifications.
- the 5' modification (loxP - neo gene - Iox2272 - PGK promoter - PB 5'LTR) and 3' modification (PB3'LTR - puro ⁇ TK gene - Iox5171 ) is depicted in Fig 23 along with the relative orientations of the lox sites and PB LTRs.
- a co- electroporated vector the DNA sequence would be inserted into the defined locus through RMCE.
- the cells in which a correct insertion has occurred can be selected as follows: (i) Puromycin-resistance (the puro ⁇ TK gene has acquired a promoter - "PGK" - from the landing pad), (ii) 6TG-resistance (the HPRT mini-gene has been disrupted), and (iii) G418-resistance (selects for any insertion via the 5' region PGK-neo arrangement). Any combination of these selection regimes can be used. G418- and 6TG-resistance select for correct events on the 5' end while puro-resistance selects for correct events on the 3' end.
- the 2 nd BAC has a length of DNA to be inserted into the genome (usually intended to be contiguous with the DNA inserted with the 1 st BAC) flanked by engineered modifications.
- the 5' modification (loxP - HPRT mini gene 5' portion - Iox5171 - PGK promoter - PB5'LTR) and 3' modification (PB3'LTR - puro ⁇ TK - Iox2272) is depicted in Fig 25 along with the relative orientations of the lox sites and PB LTRs. With transient CRE expression from a co-electroporated vector, the DNA sequence would be inserted into the defined locus through RMCE.
- the cells in which a correct insertion has occurred can be selected as follows: (i) HAT- resistance (the HPRT mini-gene is reconstituted by a correct insertion event, ie: the 5' and 3' exon structures are brought together), and (ii) puromycin-resistance (puro ⁇ TK gene has acquired a promoter - "PGK" - from the landing pad).
- the endogenous VDJ or VJ sequences can be inactivated through an inversion via chromosomal engineering as follows (see figures 27 - 29):
- PB3'LTR - PGK promoter - HPRT mini gene 5' portion - loxP - puro ⁇ TK - CAGGS promoter - PB3'LTR is depicted in Fig 27 along with the relative orientations of the lox sites and PB LTRs.
- Transient CRE expression will result in recombination between the loxP site in the "flip- over" cassette and the loxP site in the 5' modification.
- This 5' modification is as described in Steps 2 and 3 above - essentially the modification resulting from insertion of an odd number of BACs, after the 3' modification has been cured.
- the loxP sites are inverted relative to one another and therefore the described recombination event results in an inversion as depicted in Fig 28.
- Cells with the correct inversion will be HAT-resistance since the HPRT mini-gene is reconstituted by a correct inversion. 3.
- a correct inversion also leaves two transposon structures flanking the "flip-over" cassette and the 5' modification.
- Both can be excised with transient piggyBAC transposase expression, leaving no remnant of either modification (Fig 29).
- Cells with the correct excisions can be selected as follows: (i) 6TG-resistance (the HPRT mini-gene is deleted) and (ii) FIAU-resistance (the puro ⁇ TK gene is deleted).
- 6TG-resistance the HPRT mini-gene is deleted
- FIAU-resistance the puro ⁇ TK gene is deleted.
- An inversion as described in the Ig loci would move the endogenous IGH-VDJ or IGK-VJ region away from the E ⁇ or EK enhancer region, respectively, and lead to inactivation of the endogenous IGH-VDJ or IGK-VJ regions.
- the methods of insertion of the invention suitably provide one or more of:
- Figure 30 Proof of concept of the approach is disclosed in Figure 30.
- a landing pad as shown in figure 22 was inserted into the genome of a mouse by homologous recombination, followed by insertion of the R21 plasmid into that landing pad via cre-mediated site specific recombination.
- the insertion event generated a number of general insertion events, 360 G418 resistant colonies, of which ⁇ 220 were inserted into the desired locus, as demonstrated by disruption of the HRPT minilocus.
- the R21 vector mimicks the 1 st BAC insertion vector at the 5' and 3' ends, including all selection elements and recombinase target sites. In place of BAC sequences, there is a small 'stuffer' sequence. This vector will both test all the principals designed in the invention and allow easy testing of the results in that PCR across the stuffer is feasible and therefore allows both ends of the insertion to be easily tested.
- R21 was co-electroporated with a cre-expressing vector into the ES cells harbouring the landing pad in the IGH locus. Four sets of transformed cells were transfected in parallel and then placed under different selection regimes as indicated in Figure 30.
- G418 selection resulted in the largest number of colonies due to there being no requirement for specific landing-pad integration. Any integration of R21 into the genome will provide neo expression leading to G418-resistance. Puro selection resulted in a similar colony number to Puro + 6TG or G418 + 6TG, suggesting that the stringency of Puro selection is due to the Puro ⁇ TK lacking a promoter in the vector. Puro expression is only acquired when an integration occurs near a promoter element - in this design most likely specifically in the landing pad.
- the next step in the invention is to 'cure' the 3' end of the integrated BAC vector, leaving a seamless transition between the insertion and the flanking genome.
- This curing by expanding an individual clone from above (R21 inserted into the landing pad) and expressing piggyBac recombinase in this clone via transfection of an expressing plasmid.
- FIAU was used to select colonies in which the 3' modification was excised - ie, through loss of the 'PGK-puro ⁇ TK' element between the piggyBac terminal repeats.
- Fifty such clones resulted from a transfection of 10 6 cells; of these we tested 6 for the expected genomic structure.
- Successful curing resulted in positive PCR between the primer set labelled "3" in Figure 32. Of the 6 clones, 4 had correct excisions, 1 clone remained in the original configuration and 1 other had a deletion.
- Example 3 demonstrated that the design of the claimed invention was capable of providing for the insertion of a test vector into the genome at a defined location, in this case the R21 vector into the mouse IGH locus.
- the use of the appropriate selection media and the expression of cre- recombinase resulted in a genomic alteration with the predicted structure.
- BAC insert comprised human sequences from the IGH locus and was approximately 166-kb.
- This engineered BAC was electroporated along with a cre-expressing plasmid DNA into mouse ES cells harbouring the landing pad at the mouse IGH locus.
- the transfected cell population was grown in puro-containing media to select for appropriate insertion events.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (78)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012000536-7A BR112012000536A2 (en) | 2009-07-08 | 2010-07-07 | methods for producing antibody or light or heavy chain of antibody specific to a desired antigen, for producing antibody or antibody chain and its use, pharmaceutical composition and chimeric antibody derivative |
DK10734546.4T DK2421357T3 (en) | 2009-07-08 | 2010-07-07 | ANIMAL MODELS AND THERAPEUTIC MOLECULES |
SG2011096427A SG177380A1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
CA2767436A CA2767436A1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP12171793.8A EP2517557B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
CN201080040055.5A CN102638971B (en) | 2009-07-08 | 2010-07-07 | Animal model and treatment molecule |
PL10734546T PL2421357T3 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
JP2012519063A JP5944312B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP21169074.8A EP3888457B1 (en) | 2009-07-08 | 2010-07-07 | Rodent models and therapeutic molecules |
EP23161385.2A EP4215043A1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP14170196.1A EP2798950B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP14176740.0A EP2792236B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
KR1020127003297A KR101875233B1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
PL17174426T PL3241435T3 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
SI201030177T SI2421357T1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP12171791.2A EP2517556B2 (en) | 2009-07-08 | 2010-07-07 | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
ES10734546T ES2403087T3 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP20100734546 EP2421357B1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP22155461.1A EP4014729B1 (en) | 2009-07-08 | 2010-07-07 | Rodent models and therapeutic antibodies |
EP19207050.6A EP3622813B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP19207053.0A EP3622815B1 (en) | 2009-07-08 | 2010-07-07 | Rodent models and therapeutic molecules |
EP21169072.2A EP3871497B1 (en) | 2009-07-08 | 2010-07-07 | Rodent models and therapeutic molecules |
EP21169076.3A EP3871498B1 (en) | 2009-07-08 | 2010-07-07 | Rodent models and therapeutic antibodies |
NZ597481A NZ597481A (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP16151214.0A EP3028564B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP19207052.2A EP3622814B1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
AU2010269978A AU2010269978B2 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
EP17174426.1A EP3241435B1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
NZ605966A NZ605966A (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
EP18153154.2A EP3366125A1 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
PCT/GB2011/050019 WO2011158009A1 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
CN201180039668.1A CN103228130B (en) | 2010-06-17 | 2011-01-07 | Animal model and treatment molecule |
SG2012090387A SG186238A1 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
AU2011266843A AU2011266843C9 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
CN201610083094.2A CN105695415A (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
EP11705964.2A EP2582230A1 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
CA2802591A CA2802591A1 (en) | 2010-06-17 | 2011-01-07 | Animal models and therapeutic molecules |
US13/310,431 US20120204278A1 (en) | 2009-07-08 | 2011-12-02 | Animal models and therapeutic molecules |
US13/416,684 US9447177B2 (en) | 2009-07-08 | 2012-03-09 | Transgenic mouse homozygous for chimeric IgH locus |
HK12102592.4A HK1162119A1 (en) | 2009-07-08 | 2012-03-14 | Animal models and therapeutic molecules |
US13/740,727 US9505827B2 (en) | 2009-07-08 | 2013-01-14 | Animal models and therapeutic molecules |
HRP20130253AT HRP20130253T1 (en) | 2009-07-08 | 2013-03-21 | Animal models and therapeutic molecules |
SM201300046T SMT201300046B (en) | 2009-07-08 | 2013-04-23 | Animal models and therapeutic molecules |
US14/040,427 US20140201854A1 (en) | 2009-07-08 | 2013-09-27 | Animal models and therapeutic molecules |
US14/040,405 US20140201856A1 (en) | 2009-07-08 | 2013-09-27 | Animal models and therapeutic molecules |
US14/056,707 US20140150126A1 (en) | 2009-07-08 | 2013-10-17 | Animal models and therapeutic molecules |
US14/056,700 US11812731B2 (en) | 2009-07-08 | 2013-10-17 | Animal models and therapeutic molecules |
US14/056,434 US20140182003A1 (en) | 2009-07-08 | 2013-10-17 | Animal models and therapeutic molecules |
US14/080,630 US10165763B2 (en) | 2009-07-08 | 2013-11-14 | Animal models and therapeutic molecules |
US14/137,902 US9434782B2 (en) | 2009-07-08 | 2013-12-20 | Animal models and therapeutic molecules |
US14/497,054 US20150113669A1 (en) | 2009-07-08 | 2014-09-25 | Animal Models and Therapeutic Molecules |
US14/516,461 US10064398B2 (en) | 2009-07-08 | 2014-10-16 | Animal models and therapeutic molecules |
US14/750,870 US20160044900A1 (en) | 2009-07-08 | 2015-06-25 | Animal models and therapeutic molecules |
US14/818,162 US11564380B2 (en) | 2009-07-08 | 2015-08-04 | Animal models and therapeutic molecules |
US14/935,010 US9504236B2 (en) | 2009-07-08 | 2015-11-06 | Animal models and therapeutic molecules |
US15/016,211 US20160150768A1 (en) | 2009-07-08 | 2016-02-04 | Animal Models and Therapeutic Molecules |
US15/214,963 US20160345551A1 (en) | 2009-07-08 | 2016-07-20 | Animal models and therapeutic molecules |
US15/232,122 US11606941B2 (en) | 2009-07-08 | 2016-08-09 | Animal models and therapeutic molecules |
US15/251,969 US20170051045A1 (en) | 2009-07-08 | 2016-08-30 | Animal models and therapeutic molecules |
AU2016244326A AU2016244326B2 (en) | 2009-07-08 | 2016-10-14 | Animal models and therapeutic molecules |
US15/360,502 US20170071174A1 (en) | 2009-07-08 | 2016-11-23 | Animal models and therapeutic molecules |
US15/369,595 US20170081423A1 (en) | 2009-07-08 | 2016-12-05 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - Track 1 |
US15/383,188 US20170101482A1 (en) | 2009-07-08 | 2016-12-19 | Animal Models and Therapeutic Molecules |
US15/383,342 US20170099816A1 (en) | 2009-07-08 | 2016-12-19 | Animal models and therapeutic molecules |
US15/383,353 US20170094956A1 (en) | 2009-07-08 | 2016-12-19 | Animal models and therapeutic molecules |
US15/383,101 US20170099815A1 (en) | 2009-07-08 | 2016-12-19 | Animal Models and Therapeutic Molecules |
US15/385,348 US20170099817A1 (en) | 2009-07-08 | 2016-12-20 | Animal Models and Therapeutic Molecules |
US15/385,372 US20170105396A1 (en) | 2009-07-08 | 2016-12-20 | Animal Models and Therapeutic Molecules |
AU2018206729A AU2018206729C1 (en) | 2009-07-08 | 2018-07-17 | Animal models and therapeutic molecules |
US16/870,413 US20200375158A1 (en) | 2009-07-08 | 2020-05-08 | Animal Models and Therapeutic Molecules |
US16/870,365 US20200352144A1 (en) | 2009-07-08 | 2020-05-08 | Animal Models and Therapeutic Molecules |
US16/905,537 US20200337280A1 (en) | 2009-07-08 | 2020-06-18 | Animal Models and Therapeutic Molecules |
US16/905,557 US20200352145A1 (en) | 2009-07-08 | 2020-06-18 | Animal Models and Therapeutic Molecules |
AU2021200079A AU2021200079B2 (en) | 2009-07-08 | 2021-01-07 | Animal models and therapeutic molecules |
US17/943,533 US20240057572A1 (en) | 2009-07-08 | 2022-09-13 | Animal Models and Therapeutic Molecules |
US18/162,043 US20230225302A1 (en) | 2009-07-08 | 2023-01-31 | Animal Models and Therapeutic Molecules |
US18/166,813 US20230263143A1 (en) | 2009-07-08 | 2023-02-09 | Animal Models and Therapeutic Molecules |
CY20231100315T CY1126083T1 (en) | 2009-07-08 | 2023-07-05 | RODEN MODELS AND THERAPEUTIC MOLECULES |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22396009P | 2009-07-08 | 2009-07-08 | |
US61/223,960 | 2009-07-08 | ||
GBGB0911846.4A GB0911846D0 (en) | 2009-07-08 | 2009-07-08 | Animal models and therapeutic molecules |
GB0911846.4 | 2009-07-08 | ||
GB0913102.0 | 2009-07-28 | ||
GB0913102A GB0913102D0 (en) | 2009-07-28 | 2009-07-28 | Animal models and therapeutic molesules |
US35566610P | 2010-06-17 | 2010-06-17 | |
US61/355,666 | 2010-06-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/050019 Continuation-In-Part WO2011158009A1 (en) | 2009-07-08 | 2011-01-07 | Animal models and therapeutic molecules |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/050019 Continuation-In-Part WO2011158009A1 (en) | 2009-07-08 | 2011-01-07 | Animal models and therapeutic molecules |
PCT/GB2011/050019 Continuation WO2011158009A1 (en) | 2009-07-08 | 2011-01-07 | Animal models and therapeutic molecules |
US13/310,431 Continuation-In-Part US20120204278A1 (en) | 2009-07-08 | 2011-12-02 | Animal models and therapeutic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011004192A1 true WO2011004192A1 (en) | 2011-01-13 |
Family
ID=43428834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/051122 WO2011004192A1 (en) | 2009-07-08 | 2010-07-07 | Animal models and therapeutic molecules |
Country Status (23)
Country | Link |
---|---|
US (33) | US20120204278A1 (en) |
EP (19) | EP2421357B1 (en) |
JP (7) | JP5944312B2 (en) |
KR (1) | KR101875233B1 (en) |
CN (2) | CN105340834B (en) |
AU (4) | AU2010269978B2 (en) |
BR (1) | BR112012000536A2 (en) |
CA (1) | CA2767436A1 (en) |
CY (1) | CY1126083T1 (en) |
DK (12) | DK2517557T4 (en) |
ES (8) | ES2403087T3 (en) |
HK (5) | HK1172207A1 (en) |
HR (2) | HRP20130253T1 (en) |
HU (2) | HUE055817T2 (en) |
LT (1) | LT3241435T (en) |
NO (1) | NO2792236T3 (en) |
NZ (1) | NZ597481A (en) |
PL (4) | PL2564695T3 (en) |
PT (4) | PT2517556E (en) |
SG (2) | SG2014010995A (en) |
SI (2) | SI3241435T1 (en) |
SM (1) | SMT201300046B (en) |
WO (1) | WO2011004192A1 (en) |
Cited By (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120070861A1 (en) * | 2010-06-22 | 2012-03-22 | Regeneron Pharmaceuticals, Inc. | Human Lambda Light Chain Mice |
WO2012122484A1 (en) | 2011-03-09 | 2012-09-13 | Roberto Polakiewicz | Methods and reagents for creating monoclonal antibodies |
EP2501817A1 (en) | 2010-02-08 | 2012-09-26 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2550363A1 (en) | 2011-02-25 | 2013-01-30 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
AU2011266843A1 (en) * | 2010-06-17 | 2013-02-14 | Kymab Limited | Animal models and therapeutic molecules |
WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
WO2013063361A1 (en) * | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
WO2013061078A1 (en) | 2011-10-28 | 2013-05-02 | Kymab Limited | Transgenic non-human assay vertebrates, assays & kits |
WO2013079953A1 (en) | 2011-12-02 | 2013-06-06 | Kymab Limited | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
WO2013061098A3 (en) * | 2011-12-02 | 2013-06-20 | Kymab Limited | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes |
WO2013096142A1 (en) * | 2011-12-20 | 2013-06-27 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US20130212719A1 (en) * | 2012-02-01 | 2013-08-15 | Regeneron Pharmaceuticals, Inc. | Humanized Rodents that Express Heavy Chain Containing VL Domains |
EP2627773A1 (en) | 2011-10-17 | 2013-08-21 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
KR20130100277A (en) * | 2010-08-02 | 2013-09-10 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
WO2013134263A1 (en) * | 2012-03-06 | 2013-09-12 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
GB2501753A (en) * | 2012-05-04 | 2013-11-06 | Kymab Ltd | Human antibodies |
GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US20140017781A1 (en) * | 2001-02-16 | 2014-01-16 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
CN104039132A (en) * | 2011-10-28 | 2014-09-10 | 瑞泽恩制药公司 | Genetically modified major histocompatibility complex mice |
WO2014093908A3 (en) * | 2012-12-14 | 2014-10-16 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
KR20150027793A (en) * | 2012-06-12 | 2015-03-12 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US20150113669A1 (en) * | 2009-07-08 | 2015-04-23 | Kymab Limited | Animal Models and Therapeutic Molecules |
US9204624B2 (en) | 2013-02-20 | 2015-12-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modifed immunoglobulin heavy chain sequences |
CN105164153A (en) * | 2013-02-20 | 2015-12-16 | 瑞泽恩制药公司 | Mice expressing humanized T-cell co-receptors |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
WO2016063026A2 (en) | 2014-10-21 | 2016-04-28 | Kymab Ltd | Selective nav protein binders |
US9334334B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9332742B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9585373B2 (en) | 2011-10-28 | 2017-03-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
US9648856B2 (en) | 2012-03-16 | 2017-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US9700025B2 (en) | 2011-10-28 | 2017-07-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
WO2017210586A1 (en) | 2016-06-03 | 2017-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
US9957323B2 (en) | 2016-06-20 | 2018-05-01 | Kymab Limited | Anti-ICOS antibodies |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
WO2018138297A1 (en) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anti-opg antibodies |
WO2018189520A1 (en) * | 2017-04-10 | 2018-10-18 | Genome Research Limited | Animal models and therapeutic molecules |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US10154658B2 (en) | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
WO2018234575A1 (en) | 2017-06-22 | 2018-12-27 | Kymab Limited | Bispecific antibodies for factor ix and factor x |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10314296B2 (en) | 2013-02-22 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
WO2019122884A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Antibodies to icos |
WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
WO2019241692A1 (en) | 2018-06-14 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
EP3590539A1 (en) | 2014-03-04 | 2020-01-08 | Kymab Limited | Antibodies, uses & methods |
WO2020049128A1 (en) | 2018-09-06 | 2020-03-12 | Kymab Limited | Antigen-binding molecules comprising unpaired variable domains |
WO2020065252A1 (en) | 2018-09-25 | 2020-04-02 | Kymab Limited | Antagonists |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
WO2020128467A2 (en) | 2018-12-19 | 2020-06-25 | Kymab Limited | Antagonists |
US20200205384A1 (en) * | 2011-12-02 | 2020-07-02 | Kymab Limited | Transgenic Animals |
US10787522B2 (en) | 2014-03-21 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | VL antigen binding proteins exhibiting distinct binding characteristics |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
US10881084B2 (en) | 2010-07-26 | 2021-01-05 | Trianni, Inc | Transgenic animals and methods of use |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
WO2021105389A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
US11051498B2 (en) | 2017-12-05 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Mouse having an engineered immunoglobulin lambda light chain |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11259510B2 (en) | 2015-04-06 | 2022-03-01 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
WO2022140219A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
US11440960B2 (en) | 2017-06-20 | 2022-09-13 | Kymab Limited | TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
US11648308B2 (en) | 2016-05-03 | 2023-05-16 | Kymab Limited | Methods, regimens, combinations and antagonists |
RU2797272C1 (en) * | 2011-10-28 | 2023-06-01 | Регенерон Фармасьютикалз, Инк. | Genetically modified mice for t-cell receptor |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US11730151B2 (en) | 2019-02-18 | 2023-08-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
EP4173480A4 (en) * | 2020-06-25 | 2024-04-17 | Humab Co. Ltd. | Heterozygous transgenic animal |
US11997994B2 (en) | 2020-06-02 | 2024-06-04 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
US12016313B2 (en) | 2017-01-19 | 2024-06-25 | Omniab Operations, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2841376C (en) | 2011-07-05 | 2023-02-28 | Duke University | N-terminal deleted gp120 immunogens |
US10092638B2 (en) | 2011-10-03 | 2018-10-09 | Duke University | GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus |
KR102159163B1 (en) | 2012-08-03 | 2020-09-23 | 에스에이비, 엘엘씨 | Complex chromosome engineering for production of human antibodies in transgenic animals |
WO2014124156A1 (en) | 2013-02-06 | 2014-08-14 | Regeneron Pharmaceuticals, Inc. | B cell lineage based immunogen design with humanized animals |
ES2681622T3 (en) * | 2013-09-18 | 2018-09-14 | Kymab Limited | Methods, cells and organisms |
JP6174811B2 (en) | 2013-12-11 | 2017-08-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genomic modification |
MX2016016133A (en) * | 2014-06-06 | 2017-08-04 | Regeneron Pharma | Methods and compositions for modifying a targeted locus. |
DK3169778T3 (en) * | 2014-07-14 | 2023-12-18 | Univ Washington State | NANOS KNOCKOUT THAT ELIMINATES GERM CELLS |
WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
EP3222718A4 (en) * | 2014-11-20 | 2018-05-30 | Kyoto University | Method for knock-in of dna into target region of mammalian genome, and cell |
WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
RS60886B1 (en) * | 2016-11-04 | 2020-11-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
EP3558369A4 (en) * | 2016-12-21 | 2020-09-09 | Cephalon, Inc. | Antibodies that specifically bind to human il-15 and uses thereof |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
IL268660B2 (en) | 2017-02-17 | 2024-03-01 | Denali Therapeutics Inc | Engineered transferrin receptor binding polypeptides, polynucleotides encoding same and methods of producing same and methods of use thereof |
AU2018251987A1 (en) | 2017-04-14 | 2019-12-05 | Cg Oncology, Inc. | Methods of treating bladder cancer |
WO2019028190A1 (en) * | 2017-08-01 | 2019-02-07 | City Of Hope | Anti-il1rap antibodies |
KR20200085781A (en) * | 2017-10-20 | 2020-07-15 | 프레드 헛친슨 켄서 리서치 센터 | Systems and methods for producing B cells genetically modified to express selected antibodies |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
CN108486126A (en) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | A kind of nucleic acid molecules and its application in humanized antibody |
CN108486125B (en) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | Nucleic acid molecule and application thereof in preparation of humanized single domain antibody |
AU2020272939A1 (en) | 2019-04-09 | 2021-11-11 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies |
KR20230084157A (en) | 2020-10-08 | 2023-06-12 | 주식회사 휴맵 | Method for producing transgenic non-human-animals having genomes containing humanized immunoglobulin loci |
AU2022320627A1 (en) | 2021-07-26 | 2024-02-08 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
WO2023097236A1 (en) * | 2021-11-24 | 2023-06-01 | The Rockefeller University | Compositions and methods for generating immunoglobulin knock-in mice |
GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
WO1999029837A2 (en) | 1997-12-05 | 1999-06-17 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Novel dna cloning method relying on the e. coli rece/rect recombination system |
WO2001004288A1 (en) | 1999-07-09 | 2001-01-18 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
WO2002066630A1 (en) * | 2001-02-16 | 2002-08-29 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20060015957A1 (en) * | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2008076379A2 (en) * | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009076464A2 (en) * | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
Family Cites Families (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US114985A (en) * | 1871-05-16 | Improvement in apparatus for cooling and preserving milk and other liquids | ||
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US4720449A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
AU2515992A (en) * | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
DE4228162C1 (en) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Method for replacing homologous gene segments from mammals in the germline of non-human mammals |
JP4242447B2 (en) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Detection and treatment of CD40 ligand gene mutations |
DE4331162A1 (en) | 1993-09-14 | 1995-03-16 | Bayer Ag | Process for the preparation of cyanine dyes |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
AU3507297A (en) | 1996-06-26 | 1998-01-14 | Baylor College Of Medicine | Chromosomal rearrangement by insertion of two recombination substrates |
EP0937140B1 (en) | 1996-06-27 | 2007-09-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Antibody molecules which interact specifically with the active site or cleft of a target molecule |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20020088019A1 (en) | 1997-09-02 | 2002-07-04 | Oron Yacoby-Zeevi | Methods of and pharmaceutical compositions for improving implantation of embryos |
NZ504300A (en) | 1997-11-18 | 2002-06-28 | Pioneer Hi Bred Int | A method for directional stable transformation of eukaryotic cells using non-identical recombination sites |
EP0939120A1 (en) | 1998-02-27 | 1999-09-01 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells |
NZ509241A (en) | 1998-08-07 | 2003-08-29 | Du Pont Pharm Co | Succinoylamino lactams as inhibitors of alpha-beta protein production |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
AU5867100A (en) | 1999-05-03 | 2000-12-12 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2307503A1 (en) * | 2000-05-02 | 2001-11-02 | Carlos F. Barbas Iii | Peptides for use as a vaccine or treatment for hiv infection |
JP2004504055A (en) * | 2000-07-21 | 2004-02-12 | アメリカ合衆国 | Methods of DNA replacement, translocation and stacking in eukaryotic genomes |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002219841A1 (en) * | 2000-11-16 | 2002-05-27 | Cornell Research Foundation Inc. | Vectors for conditional gene inactivation |
EP1343880B1 (en) | 2000-11-17 | 2009-05-27 | Kyowa Hakko Kirin Co., Ltd. | Expression of xenogenous (human) immunoglobulins in cloned, transgenic bovine |
JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
EP1409646B1 (en) * | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
PE20020801A1 (en) | 2001-01-05 | 2002-09-06 | Pfizer | ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR RECEPTOR |
AUPR446701A0 (en) * | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
JP2003000243A (en) | 2001-06-25 | 2003-01-07 | Takachika Azuma | Method for producing mutant |
FR2827302B1 (en) * | 2001-07-13 | 2003-10-10 | Genoway | TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF |
WO2003017336A2 (en) | 2001-08-13 | 2003-02-27 | Amberwave Systems Corporation | Dram trench capacitor and method of making the same |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
WO2003031656A1 (en) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
CA2847885C (en) | 2001-11-30 | 2022-03-22 | Amgen Fremont Inc. | Transgenic animals bearing human ig.lambda. light chain genes |
US20050095712A1 (en) | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
PT1523496E (en) | 2002-07-18 | 2011-09-29 | Merus B V | Recombinant production of mixtures of antibodies |
AU2003278790A1 (en) | 2002-09-09 | 2004-03-29 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
CA2501981A1 (en) * | 2002-10-01 | 2004-04-15 | Mitos Pharmaceuticals, Inc. | Nitroxide radioprotector formulations and methods of use |
DE10251918A1 (en) * | 2002-11-08 | 2004-05-19 | Horn, Carsten, Dipl.-Biochem. Dr. | Inheritable integration of DNA into germ-line invertebrate cells, useful for large-scale production of transgenic insects, includes post-transformational removal of mobilizable elements to increase stability |
US7700356B2 (en) * | 2002-11-08 | 2010-04-20 | The United States Of America As Represented By The Secretary Of Agriculture | System for gene targeting and producing stable genomic transgene insertions |
AR042145A1 (en) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
CN1326878C (en) * | 2003-04-29 | 2007-07-18 | 中国抗体制药有限公司 | Anti human non-Hodgkin's lymphoma chimeric antibody and its derivative and application |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US7205148B2 (en) | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
GB2403475B (en) * | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
WO2005007696A2 (en) * | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
US7604994B2 (en) | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
US7205140B2 (en) | 2003-10-20 | 2007-04-17 | Campusgen Gmbh | Nucleotide sequence for creatinine deiminase and method of use |
PL1691837T3 (en) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | Ip-10 antibodies and their uses |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
CA2564989C (en) | 2004-03-19 | 2014-05-27 | Amgen, Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
EP1978032A3 (en) | 2004-07-22 | 2009-02-18 | Erasmus University Medical Center Rotterdam | Binding molecules |
FR2875239B1 (en) | 2004-09-10 | 2007-07-20 | Inst Necker Ass Loi De 1901 | METHOD FOR THE ACCELERATION OF SOMATIC MUTATIONS AND ITS APPLICATION IN PROTEOMICS |
WO2006029459A1 (en) | 2004-09-13 | 2006-03-23 | Evogenix, Inc | Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof |
WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
PL1802193T3 (en) † | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Method for generating a mouse homozygous for a genetic modification |
JP2008517600A (en) * | 2004-10-22 | 2008-05-29 | セラピューティック ヒューマン ポリクローナルズ, インコーポレイテッド | Suppression of endogenous immunoglobulin expression in non-human transgenic animals |
WO2006055704A2 (en) | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
EP2284194A1 (en) | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006117699A2 (en) | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
US20100154070A1 (en) * | 2005-05-14 | 2010-06-17 | Tian Xu | PiggyBac as a Tool for Genetic Manipulation and Analysis in Vertebrates |
EP1780272A1 (en) | 2005-10-27 | 2007-05-02 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method for enhancing somatic hypermutation, gene conversion and class switch recombination |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
KR101481843B1 (en) | 2006-01-25 | 2015-01-12 | 에라스무스 유니버시티 메디컬 센터 로테르담 | Generation of heavy-chain only antibodies in transgenic animals |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
AU2007345747A1 (en) * | 2006-06-27 | 2008-08-07 | Vaxdesign Corporation | Models for vaccine assessment |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
US8084024B2 (en) | 2006-08-22 | 2011-12-27 | G2 Inflammation Pty Ltd | Method for producing antibodies |
US7778624B2 (en) * | 2006-09-01 | 2010-08-17 | Wanda Ying Li | Outdoor umbrella with audio system |
MX2009003393A (en) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor. |
US7732195B2 (en) * | 2006-11-01 | 2010-06-08 | Facet Biotech Corporation | Tethered vectors for cell surface immunoglobulin display |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
WO2008103474A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
ES2456961T3 (en) | 2007-02-21 | 2014-04-24 | University Of Massachusetts | Human antibodies against hepatitis C virus (HCV), uses thereof |
EP2132312B1 (en) | 2007-03-27 | 2016-01-27 | Sea Lane Biotechnologies,llc. | Constructs and libraries comprising antibody surrogate light chain sequences |
GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
LT2602323T (en) | 2007-06-01 | 2018-04-10 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
EP2178916B1 (en) | 2007-07-31 | 2014-12-17 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human cd20 and method of using thereof |
US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
MX2010001395A (en) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor. |
DK2592148T3 (en) * | 2007-10-12 | 2018-12-10 | Hoffmann La Roche | Protein expression from multiple nucleic acids |
US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
BRPI0906711A2 (en) | 2008-01-25 | 2015-06-30 | Cabot Corp | Modulus for preparation of modified colored pigment |
KR101409375B1 (en) | 2008-01-31 | 2014-06-18 | 삼성전자주식회사 | Block decoding circuit of semiconductor memory device |
WO2009118524A2 (en) | 2008-03-26 | 2009-10-01 | Iti Scotland Limited | Efficient insertion of dna into embryonic stem cells |
US8012714B2 (en) | 2008-04-14 | 2011-09-06 | Innovative Targeting Solutions, Inc. | Sequence diversity generation in immunoglobulins |
KR20110029156A (en) | 2008-06-27 | 2011-03-22 | 메뤼스 베.페. | Antibody producing non-human mammals |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
US20110314563A1 (en) | 2008-12-18 | 2011-12-22 | Kingdon Craig R | Antibody production |
US9085795B2 (en) | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
US20110305692A1 (en) | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
CA2757178C (en) | 2009-04-03 | 2020-05-19 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
EP2446032B8 (en) | 2009-06-26 | 2017-03-15 | i2 Pharmaceuticals, Inc. | Expression of surrogate light chains |
HUE055817T2 (en) | 2009-07-08 | 2021-12-28 | Kymab Ltd | Animal models and therapeutic molecules |
GB0913102D0 (en) | 2009-07-28 | 2009-09-02 | Genome Res Ltd | Animal models and therapeutic molesules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
GB0911846D0 (en) | 2009-07-08 | 2009-08-19 | Genome Res Ltd | Animal models and therapeutic molecules |
CA2768207C (en) | 2009-07-15 | 2019-12-03 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
JO3182B1 (en) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
WO2011019844A1 (en) | 2009-08-13 | 2011-02-17 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal cdrs |
US20120251552A1 (en) | 2009-11-05 | 2012-10-04 | Anaptysbio, Inc. | Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation |
CN102741404B (en) | 2009-11-17 | 2017-03-08 | Sab有限责任公司 | human artificial chromosome vector |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
CN102711449B (en) | 2009-12-10 | 2015-01-07 | 瑞泽恩制药公司 | Mice that make heavy chain antibodies |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
NZ719253A (en) | 2010-02-08 | 2022-08-26 | Regeneron Pharma | Common light chain mouse |
JP6208580B2 (en) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス, インコーポレイテッド | Novel DNA binding protein and use thereof |
EP2582230A1 (en) | 2010-06-17 | 2013-04-24 | Kymab Limited | Animal models and therapeutic molecules |
DK2480676T3 (en) | 2010-06-22 | 2016-06-20 | Regeneron Pharma | MICE EXPRESSING A HYDRIDE immunoglobulin light chain |
EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
JO3375B1 (en) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | Human antibodies to human tnf-like ligand 1a (tl1a) |
AU2011348232A1 (en) | 2010-12-22 | 2013-07-18 | Genentech, Inc. | Anti-PCSK9 antibodies and methods of use |
US8642835B2 (en) | 2011-02-25 | 2014-02-04 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
SG2014007686A (en) | 2011-08-05 | 2014-03-28 | Regeneron Pharma | Humanized universal light chain mice |
EP3741862A1 (en) | 2011-09-19 | 2020-11-25 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
CN103945689B (en) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | The multifarious manipulation of immunoglobulin gene and multispecific antibody therapeutic agent |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US20130102031A1 (en) | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US20180295821A1 (en) | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
BR112014015238B1 (en) | 2011-12-20 | 2022-11-16 | Regeneron Pharmaceuticals, Inc | EX VIVO METHOD FOR PREPARING AN ANTIBODY THAT BINDS TO AN ANTIGEN OF INTEREST, INCLUDING IDENTIFYING NUCLEIC ACID SEQUENCES FROM MOUSE B LYMPHOCYTES GENETICALLY MODIFIED BY PLACING AN ADAM6 GENE |
DK3597038T3 (en) | 2012-02-01 | 2021-06-28 | Regeneron Pharma | Humanized rodents expressing heavy chains containing VL domains |
RU2017127772A (en) | 2012-03-02 | 2019-02-04 | Регенерон Фармасьютикалз, Инк. | HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS |
SG11201405088QA (en) | 2012-03-06 | 2014-11-27 | Regeneron Pharma | Common light chain mouse |
CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
DK2800811T3 (en) | 2012-05-25 | 2017-07-17 | Univ Vienna | METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION |
US8518765B1 (en) | 2012-06-05 | 2013-08-27 | Intermolecular, Inc. | Aqua regia and hydrogen peroxide HCl combination to remove Ni and NiPt residues |
PT2858487T (en) | 2012-06-12 | 2020-01-15 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US8962913B2 (en) * | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
CN105755009A (en) | 2012-11-09 | 2016-07-13 | 深圳市作物分子设计育种研究院 | Fertility gene and application thereof |
ES2658401T3 (en) | 2012-12-12 | 2018-03-09 | The Broad Institute, Inc. | Supply, modification and optimization of systems, methods and compositions for the manipulation of sequences and therapeutic applications |
MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) * | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US20140331344A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Ltd. | Transgenic Animals |
US20140331339A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Limited | Transgenic Non-Human Assay Vertebrates, Assays and Kits |
SG10201802295XA (en) | 2013-10-01 | 2018-04-27 | Kymab Ltd | Animal Models and Therapeutic Molecules |
GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
JP7087648B2 (en) * | 2018-05-08 | 2022-06-21 | トヨタ自動車株式会社 | Battery pack |
-
2010
- 2010-07-07 HU HUE17174426A patent/HUE055817T2/en unknown
- 2010-07-07 JP JP2012519063A patent/JP5944312B2/en active Active
- 2010-07-07 DK DK12171793.8T patent/DK2517557T4/en active
- 2010-07-07 EP EP20100734546 patent/EP2421357B1/en not_active Revoked
- 2010-07-07 SG SG2014010995A patent/SG2014010995A/en unknown
- 2010-07-07 KR KR1020127003297A patent/KR101875233B1/en active IP Right Review Request
- 2010-07-07 PL PL12194970T patent/PL2564695T3/en unknown
- 2010-07-07 CN CN201510587176.6A patent/CN105340834B/en active Active
- 2010-07-07 PT PT121717912T patent/PT2517556E/en unknown
- 2010-07-07 DK DK16151215.7T patent/DK3028565T3/en active
- 2010-07-07 PT PT171744261T patent/PT3241435T/en unknown
- 2010-07-07 ES ES10734546T patent/ES2403087T3/en active Active
- 2010-07-07 ES ES21169074T patent/ES2978496T3/en active Active
- 2010-07-07 DK DK19207053.0T patent/DK3622815T3/en active
- 2010-07-07 EP EP21169074.8A patent/EP3888457B1/en active Active
- 2010-07-07 ES ES21169072T patent/ES2974417T3/en active Active
- 2010-07-07 EP EP19207050.6A patent/EP3622813B2/en active Active
- 2010-07-07 ES ES19207052T patent/ES2965212T3/en active Active
- 2010-07-07 CA CA2767436A patent/CA2767436A1/en active Pending
- 2010-07-07 WO PCT/GB2010/051122 patent/WO2011004192A1/en active Application Filing
- 2010-07-07 EP EP23161385.2A patent/EP4215043A1/en active Pending
- 2010-07-07 HU HUE19207053A patent/HUE061788T2/en unknown
- 2010-07-07 DK DK16151214.0T patent/DK3028564T5/en active
- 2010-07-07 EP EP21169072.2A patent/EP3871497B1/en active Active
- 2010-07-07 EP EP21169076.3A patent/EP3871498B1/en active Active
- 2010-07-07 EP EP16151214.0A patent/EP3028564B2/en active Active
- 2010-07-07 EP EP19207052.2A patent/EP3622814B1/en active Active
- 2010-07-07 ES ES12194970.5T patent/ES2537239T3/en active Active
- 2010-07-07 PL PL17174426T patent/PL3241435T3/en unknown
- 2010-07-07 EP EP16151215.7A patent/EP3028565B1/en not_active Revoked
- 2010-07-07 DK DK14176740.0T patent/DK2792236T4/en active
- 2010-07-07 DK DK19207050.6T patent/DK3622813T4/en active
- 2010-07-07 SG SG2011096427A patent/SG177380A1/en unknown
- 2010-07-07 EP EP14176740.0A patent/EP2792236B2/en active Active
- 2010-07-07 EP EP22155461.1A patent/EP4014729B1/en active Active
- 2010-07-07 EP EP12171793.8A patent/EP2517557B2/en active Active
- 2010-07-07 ES ES17174426T patent/ES2884309T3/en active Active
- 2010-07-07 EP EP12194977.0A patent/EP2604110B1/en not_active Revoked
- 2010-07-07 NZ NZ597481A patent/NZ597481A/en unknown
- 2010-07-07 EP EP20120195041 patent/EP2604111A3/en not_active Withdrawn
- 2010-07-07 DK DK10734546.4T patent/DK2421357T3/en active
- 2010-07-07 EP EP19207053.0A patent/EP3622815B1/en active Active
- 2010-07-07 EP EP12171791.2A patent/EP2517556B2/en active Active
- 2010-07-07 DK DK12171791.2T patent/DK2517556T4/en active
- 2010-07-07 AU AU2010269978A patent/AU2010269978B2/en active Active
- 2010-07-07 PT PT107345464T patent/PT2421357E/en unknown
- 2010-07-07 CN CN201080040055.5A patent/CN102638971B/en active Active
- 2010-07-07 EP EP17174426.1A patent/EP3241435B1/en active Active
- 2010-07-07 PL PL10734546T patent/PL2421357T3/en unknown
- 2010-07-07 DK DK14170196.1T patent/DK2798950T4/en active
- 2010-07-07 BR BR112012000536-7A patent/BR112012000536A2/en not_active Application Discontinuation
- 2010-07-07 EP EP20120194970 patent/EP2564695B1/en not_active Revoked
- 2010-07-07 ES ES12171791.2T patent/ES2557737T3/en active Active
- 2010-07-07 DK DK12194977.0T patent/DK2604110T3/en active
- 2010-07-07 NO NO14176740A patent/NO2792236T3/no unknown
- 2010-07-07 DK DK12194970.5T patent/DK2564695T3/en active
- 2010-07-07 LT LTEP17174426.1T patent/LT3241435T/en unknown
- 2010-07-07 SI SI201032086T patent/SI3241435T1/en unknown
- 2010-07-07 SI SI201030177T patent/SI2421357T1/en unknown
- 2010-07-07 ES ES19207053T patent/ES2948572T3/en active Active
- 2010-07-07 EP EP14170196.1A patent/EP2798950B2/en active Active
- 2010-07-07 PL PL12171791T patent/PL2517556T3/en unknown
- 2010-07-07 PT PT121949705T patent/PT2564695E/en unknown
- 2010-07-07 DK DK17174426.1T patent/DK3241435T3/en active
-
2011
- 2011-12-02 US US13/310,431 patent/US20120204278A1/en not_active Abandoned
-
2012
- 2012-03-09 US US13/416,684 patent/US9447177B2/en active Active
- 2012-03-14 HK HK12113213.0A patent/HK1172207A1/en active IP Right Maintenance
- 2012-03-14 HK HK12102592.4A patent/HK1162119A1/en not_active IP Right Cessation
- 2012-03-14 HK HK13107869.8A patent/HK1180535A1/en not_active IP Right Cessation
- 2012-03-14 HK HK15102886.6A patent/HK1202373A1/en active IP Right Maintenance
- 2012-03-14 HK HK15101569.2A patent/HK1201026A1/en active IP Right Maintenance
-
2013
- 2013-01-14 US US13/740,727 patent/US9505827B2/en active Active
- 2013-03-21 HR HRP20130253AT patent/HRP20130253T1/en unknown
- 2013-04-23 SM SM201300046T patent/SMT201300046B/en unknown
- 2013-09-27 US US14/040,427 patent/US20140201854A1/en not_active Abandoned
- 2013-09-27 US US14/040,405 patent/US20140201856A1/en not_active Abandoned
- 2013-10-17 US US14/056,700 patent/US11812731B2/en active Active
- 2013-10-17 US US14/056,707 patent/US20140150126A1/en not_active Abandoned
- 2013-10-17 US US14/056,434 patent/US20140182003A1/en not_active Abandoned
- 2013-11-14 US US14/080,630 patent/US10165763B2/en active Active
- 2013-12-20 US US14/137,902 patent/US9434782B2/en active Active
-
2014
- 2014-09-25 US US14/497,054 patent/US20150113669A1/en not_active Abandoned
- 2014-10-16 US US14/516,461 patent/US10064398B2/en active Active
-
2015
- 2015-02-06 JP JP2015022430A patent/JP6088562B2/en active Active
- 2015-06-25 US US14/750,870 patent/US20160044900A1/en not_active Abandoned
- 2015-08-04 US US14/818,162 patent/US11564380B2/en active Active
-
2016
- 2016-02-04 US US15/016,211 patent/US20160150768A1/en not_active Abandoned
- 2016-07-20 US US15/214,963 patent/US20160345551A1/en not_active Abandoned
- 2016-08-09 US US15/232,122 patent/US11606941B2/en active Active
- 2016-08-30 US US15/251,969 patent/US20170051045A1/en not_active Abandoned
- 2016-10-14 AU AU2016244326A patent/AU2016244326B2/en active Active
- 2016-11-23 US US15/360,502 patent/US20170071174A1/en not_active Abandoned
- 2016-12-19 US US15/383,101 patent/US20170099815A1/en not_active Abandoned
- 2016-12-19 US US15/383,188 patent/US20170101482A1/en not_active Abandoned
- 2016-12-19 US US15/383,353 patent/US20170094956A1/en not_active Abandoned
- 2016-12-19 US US15/383,342 patent/US20170099816A1/en not_active Abandoned
- 2016-12-20 US US15/385,348 patent/US20170099817A1/en not_active Abandoned
- 2016-12-20 US US15/385,372 patent/US20170105396A1/en not_active Abandoned
-
2017
- 2017-02-02 JP JP2017017360A patent/JP6612275B2/en active Active
-
2018
- 2018-07-17 AU AU2018206729A patent/AU2018206729C1/en active Active
-
2019
- 2019-10-30 JP JP2019197622A patent/JP6930695B2/en active Active
-
2020
- 2020-05-08 US US16/870,413 patent/US20200375158A1/en not_active Abandoned
- 2020-05-08 US US16/870,365 patent/US20200352144A1/en active Pending
- 2020-06-15 JP JP2020102977A patent/JP7141427B2/en active Active
- 2020-06-15 JP JP2020102976A patent/JP6876853B2/en active Active
- 2020-06-15 JP JP2020102978A patent/JP6876854B2/en active Active
- 2020-06-18 US US16/905,557 patent/US20200352145A1/en not_active Abandoned
- 2020-06-18 US US16/905,537 patent/US20200337280A1/en active Pending
-
2021
- 2021-01-07 AU AU2021200079A patent/AU2021200079B2/en active Active
- 2021-08-04 HR HRP20211253TT patent/HRP20211253T1/en unknown
-
2022
- 2022-09-13 US US17/943,533 patent/US20240057572A1/en active Pending
- 2022-11-29 US US18/059,809 patent/US20230270088A1/en active Pending
-
2023
- 2023-01-31 US US18/162,043 patent/US20230225302A1/en active Pending
- 2023-02-09 US US18/166,813 patent/US20230263143A1/en active Pending
- 2023-07-05 CY CY20231100315T patent/CY1126083T1/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060015957A1 (en) * | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
WO1999029837A2 (en) | 1997-12-05 | 1999-06-17 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Novel dna cloning method relying on the e. coli rece/rect recombination system |
WO2001004288A1 (en) | 1999-07-09 | 2001-01-18 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
WO2002066630A1 (en) * | 2001-02-16 | 2002-08-29 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
WO2007117410A2 (en) | 2006-03-31 | 2007-10-18 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2008076379A2 (en) * | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
WO2009013620A2 (en) * | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009076464A2 (en) * | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
Non-Patent Citations (16)
Title |
---|
ADAMS DJ; QUAIL MA; COX T; VAN DER WEYDEN L; GORICK BD; SU Q; CHAN WI; DAVIES R; BONFIELD JK; LAW F: "A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction", GENOMICS, vol. 86, no. 6, 27 October 2005 (2005-10-27), pages 753 - 8 |
BARRETT, M.T.; SCHEFFER, A.; BEN-DOR, A.; SAMPAS, N.; LIPSON, D.; KINCAID, R.; TSANG, P.; CURRY, B.; BAIRD, K.; MELTZER, P.S. ET A: "Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, 2004, pages 17765 - 17770 |
CHAN, W.; COSTANTINO, N.; LI, R.; LEE, S.C.; SU, Q.; MELVIN, D.; COURT, D.L.; LIU, P.: "A recombineering based approach for high-throughput conditional knockout targeting vector construction", NUCLEIC ACIDS RESEARCH, vol. 35, 2007, pages E64 |
CHUNG, Y.J.; JONKERS, J.; KITSON, H.; FIEGLER, H.; HUMPHRAY, S.; SCOTT, C.; HUNT, S.; YU, Y.; NISHIJIMA, I.; VELDS, A. ET AL.: "A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization", GENOME RESEARCH, vol. 14, 2004, pages 188 - 196 |
LIANG, Q.; CONTE, N.; SKARNES, W.C.; BRADLEY, A.: "Extensive genomic copy number variation in embryonic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, 2008, pages 17453 - 17456 |
OSOEGAWA K ET AL., GENOME RESEARCH, vol. 11, 2001, pages 483 - 496 |
PASQUALINI; ARAP, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 101, 2004, pages 257 - 259 |
PETTITT, S.J.; LIANG, Q.; RAIRDAN, X.Y.; MORAN, J.L.; PROSSER, H.M.; BEIER, D.R.; LLOYD, K.C.; BRADLEY, A.; SKARNES, W.C.: "Agouti C57BL/6N embryonic stem cells for mouse genetic resources", NATURE METHODS., 2009 |
PETTITT, S.J.; LIANG, Q.; RAIRDAN, X.Y.; MORAN, J.L.; PROSSER, H.M.; BEIER, D.R.; LLOYD, K.C.; BRADLEY, A.; SKARNES, W.C.: "Agouti C57BU6N embryonic stem cells for mouse genetic resources", NATURE METHODS., 2009 |
PROSSER, H.M. ET AL.: "Mosaic complementation demonstrates a regulatory role for myosin V a in actin dynamics of Stereocilia", MOL. CELL. BIOL., vol. 28, 2008, pages 1702 - 12 |
PROSSER, H.M.; RZADZINSKA, A.K.; STEEL, K.P.; BRADLEY, A.: "Mosaic complementation demonstrates a regulatory role for myosin V a in actin dynamics of stereocilia", MOLECULAR AND CELLULAR BIOLOGY, vol. 28, 2008, pages 1702 - 1712 |
RAMFREZ-SOLIS R; LIU P; BRADLEY A: "Chromosome engineering in mice", NATURE, vol. 378, no. 6558, 1995, pages 720 - 4 |
RAMIREZ-SOLIS, R.; DAVIS, A.C.; BRADLEY, A.: "Gene targeting in embryonic stem cells", METHODS IN ENZYMOLOGY, vol. 225, 1993, pages 855 - 878 |
SCHLAKE, T.; J. BODE: "Use of mutated FLP-recognition-target-(FRT-)sites for the exchange of expression cassettes at defined chromosomal loci", BIOCHEMISTRY, vol. 33, 1994, pages 12746 - 12751 |
WALLACE, H.A.C. ET AL.: "Manipulating the mouse genome to engineering precise functional syntenic replacements with human sequence", CELL, vol. 128, 2007, pages 197 - 209 |
ZHENG ET AL., NAR, vol. 27, no. 11, 1999, pages 2354 - 2360 |
Cited By (441)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10227625B2 (en) | 2000-10-31 | 2019-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US10640800B2 (en) | 2001-02-16 | 2020-05-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US20140017781A1 (en) * | 2001-02-16 | 2014-01-16 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
US10526630B2 (en) | 2001-02-16 | 2020-01-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice that produce hybrid antibodies |
US10378040B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US10378039B2 (en) * | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus |
US10492476B2 (en) | 2008-09-30 | 2019-12-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10638736B2 (en) | 2008-09-30 | 2020-05-05 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10575504B2 (en) | 2008-09-30 | 2020-03-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10561123B2 (en) | 2008-09-30 | 2020-02-18 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10555506B2 (en) | 2008-09-30 | 2020-02-11 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10064398B2 (en) | 2009-07-08 | 2018-09-04 | Kymab Limited | Animal models and therapeutic molecules |
US9447177B2 (en) | 2009-07-08 | 2016-09-20 | Kymab Limited | Transgenic mouse homozygous for chimeric IgH locus |
US10165763B2 (en) | 2009-07-08 | 2019-01-01 | Kymab Limited | Animal models and therapeutic molecules |
US9505827B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
EP2517556B1 (en) | 2009-07-08 | 2015-11-18 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
US9434782B2 (en) | 2009-07-08 | 2016-09-06 | Kymab Limited | Animal models and therapeutic molecules |
US11812731B2 (en) | 2009-07-08 | 2023-11-14 | Kymab Ltd. | Animal models and therapeutic molecules |
US11606941B2 (en) | 2009-07-08 | 2023-03-21 | Kymab Limited | Animal models and therapeutic molecules |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US20150113669A1 (en) * | 2009-07-08 | 2015-04-23 | Kymab Limited | Animal Models and Therapeutic Molecules |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2501817A1 (en) | 2010-02-08 | 2012-09-26 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
US10412940B2 (en) | 2010-02-08 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10986820B2 (en) | 2010-02-08 | 2021-04-27 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US11026407B2 (en) | 2010-02-08 | 2021-06-08 | Regeneran Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10167344B2 (en) | 2010-02-08 | 2019-01-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10494445B2 (en) | 2010-03-31 | 2019-12-03 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10526420B2 (en) | 2010-03-31 | 2020-01-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10836832B2 (en) | 2010-03-31 | 2020-11-17 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10662255B2 (en) | 2010-03-31 | 2020-05-26 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10626188B2 (en) | 2010-03-31 | 2020-04-21 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10618977B2 (en) | 2010-03-31 | 2020-04-14 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10604587B2 (en) | 2010-03-31 | 2020-03-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11242409B2 (en) | 2010-03-31 | 2022-02-08 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10829564B2 (en) | 2010-03-31 | 2020-11-10 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11220555B2 (en) | 2010-03-31 | 2022-01-11 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11104744B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11352444B2 (en) | 2010-03-31 | 2022-06-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11104743B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
EP2582230A1 (en) * | 2010-06-17 | 2013-04-24 | Kymab Limited | Animal models and therapeutic molecules |
AU2011266843A1 (en) * | 2010-06-17 | 2013-02-14 | Kymab Limited | Animal models and therapeutic molecules |
AU2011266843C9 (en) * | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
AU2011266843C1 (en) * | 2010-06-17 | 2018-02-01 | Kymab Limited | Animal models and therapeutic molecules |
US9850462B2 (en) | 2010-06-22 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
US9150662B2 (en) | 2010-06-22 | 2015-10-06 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
EP2480676A1 (en) | 2010-06-22 | 2012-08-01 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
EP2480675A1 (en) | 2010-06-22 | 2012-08-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing alight chain with human lambda variable and mouse constant regions |
KR101945352B1 (en) | 2010-06-22 | 2019-02-07 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
KR20180135996A (en) * | 2010-06-22 | 2018-12-21 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR20180135997A (en) * | 2010-06-22 | 2018-12-21 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR20190014576A (en) * | 2010-06-22 | 2019-02-12 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
KR20190014578A (en) * | 2010-06-22 | 2019-02-12 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
EP3456832A1 (en) * | 2010-06-22 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Mice expressing an immunoglobulin hybrid light chain |
US20120070861A1 (en) * | 2010-06-22 | 2012-03-22 | Regeneron Pharmaceuticals, Inc. | Human Lambda Light Chain Mice |
US10266803B2 (en) | 2010-06-22 | 2019-04-23 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
EP2568049A1 (en) * | 2010-06-22 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Mice expressing an immunoglobulin hybrid light chain with a human variable region |
KR101970944B1 (en) | 2010-06-22 | 2019-04-23 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR20210134424A (en) * | 2010-06-22 | 2021-11-09 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR102320944B1 (en) | 2010-06-22 | 2021-11-04 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR20190049932A (en) * | 2010-06-22 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
US9006511B2 (en) | 2010-06-22 | 2015-04-14 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
US9012717B2 (en) | 2010-06-22 | 2015-04-21 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
KR101975884B1 (en) | 2010-06-22 | 2019-05-10 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR101991234B1 (en) | 2010-06-22 | 2019-06-20 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
KR20190073584A (en) * | 2010-06-22 | 2019-06-26 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
US9029628B2 (en) | 2010-06-22 | 2015-05-12 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
US9035128B2 (en) | 2010-06-22 | 2015-05-19 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
KR102001430B1 (en) | 2010-06-22 | 2019-07-18 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
US20150173331A1 (en) * | 2010-06-22 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Human Lambda Light Chain Mice |
US9066502B2 (en) | 2010-06-22 | 2015-06-30 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
KR20190142436A (en) * | 2010-06-22 | 2019-12-26 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
CN103068993A (en) * | 2010-06-22 | 2013-04-24 | 瑞泽恩制药公司 | Hybrid light chain mice |
KR102059909B1 (en) | 2010-06-22 | 2019-12-27 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
EP2905338A1 (en) * | 2010-06-22 | 2015-08-12 | Regeneron Pharmaceuticals, Inc. | Trangenic mice with a modified endogenous lambda immunoglobulin locus |
CN103068994A (en) * | 2010-06-22 | 2013-04-24 | 瑞泽恩制药公司 | Mice expressing alight chain with human lambda variable and mouse constant regions |
KR102266097B1 (en) | 2010-06-22 | 2021-06-18 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
US20130323790A1 (en) * | 2010-06-22 | 2013-12-05 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
US9163092B2 (en) | 2010-06-22 | 2015-10-20 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
JP2018023403A (en) * | 2010-06-22 | 2018-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Hybrid light chain mouse |
US9206263B2 (en) | 2010-06-22 | 2015-12-08 | Regeneron Pharmaceuticals, Inc. | Method of making antibodies using a human lambda light chain mouse |
US9206262B2 (en) | 2010-06-22 | 2015-12-08 | Regeneron Pharmaceuticals, Inc. | Method of cloning a lambda light chain variable domain using a human lambda light chain mouse |
KR20210073609A (en) * | 2010-06-22 | 2021-06-18 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
US9206261B2 (en) | 2010-06-22 | 2015-12-08 | Regeneron Pharmaceuticals, Inc. | Method of making antibodies using a human lambda light chain mouse |
US9226484B2 (en) | 2010-06-22 | 2016-01-05 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
CN103068993B (en) * | 2010-06-22 | 2016-01-06 | 瑞泽恩制药公司 | Hybrid light chain mice |
KR102506001B1 (en) | 2010-06-22 | 2023-03-07 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
CN103068994B (en) * | 2010-06-22 | 2016-01-20 | 瑞泽恩制药公司 | Express the mouse with the light chain of people λ variable region and murine constant region |
KR101934852B1 (en) | 2010-06-22 | 2019-01-04 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
JP2016010417A (en) * | 2010-06-22 | 2016-01-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
JP2016010415A (en) * | 2010-06-22 | 2016-01-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | MICE EXPRESSING LIGHT CHAIN WITH HUMAN λ VARIABLE REGION AND MOUSE CONSTANT REGION |
US9844212B2 (en) | 2010-06-22 | 2017-12-19 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
JP2013531501A (en) * | 2010-06-22 | 2013-08-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Hybrid light chain mouse |
KR102211911B1 (en) | 2010-06-22 | 2021-02-05 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
JP2013532974A (en) * | 2010-06-22 | 2013-08-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Mice expressing a light chain comprising a human λ variable region and a mouse constant region |
KR20210013376A (en) * | 2010-06-22 | 2021-02-03 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
EP2480676B1 (en) * | 2010-06-22 | 2016-04-06 | Regeneron Pharmaceuticals, Inc. | Mice expressing an immunoglobulin hybrid light chain |
EP2480675B1 (en) * | 2010-06-22 | 2016-04-06 | Regeneron Pharmaceuticals, Inc. | Mice expressing a light chain with human lambda variable and mouse constant regions |
KR102118565B1 (en) | 2010-06-22 | 2020-06-03 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
KR20200064166A (en) * | 2010-06-22 | 2020-06-05 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
US9334333B2 (en) | 2010-06-22 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Hybrid light chain mice |
EP3034608A1 (en) * | 2010-06-22 | 2016-06-22 | Regeneron Pharmaceuticals, Inc. | Mice expressing an immunoglobulin hybrid light chain |
KR102193823B1 (en) | 2010-06-22 | 2020-12-22 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
US9540452B2 (en) | 2010-06-22 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
KR20200143511A (en) * | 2010-06-22 | 2020-12-23 | 리제너론 파아마슈티컬스, 인크. | Hybrid light chain mice |
US9394373B2 (en) | 2010-06-22 | 2016-07-19 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
US9399683B2 (en) | 2010-06-22 | 2016-07-26 | Regeneron Pharmaceuticals, Inc. | Human lambda light chain mice |
KR102462042B1 (en) | 2010-06-22 | 2022-11-03 | 리제너론 파아마슈티컬스, 인크. | Mice expressing a light chain with human lambda variable and mouse constant regions |
US10881084B2 (en) | 2010-07-26 | 2021-01-05 | Trianni, Inc | Transgenic animals and methods of use |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US12049516B2 (en) | 2010-07-26 | 2024-07-30 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
KR20200116547A (en) * | 2010-08-02 | 2020-10-12 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
KR20130100277A (en) * | 2010-08-02 | 2013-09-10 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
KR20190095511A (en) * | 2010-08-02 | 2019-08-14 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
KR102008655B1 (en) | 2010-08-02 | 2019-08-08 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
JP7110257B2 (en) | 2010-08-02 | 2022-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Mice making binding proteins containing VL domains |
KR102434557B1 (en) | 2010-08-02 | 2022-08-23 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
US9516868B2 (en) | 2010-08-02 | 2016-12-13 | Regeneron Pharmaceuticals, Inc. | Mice that make VL binding proteins |
US20210163628A1 (en) * | 2010-08-02 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Mice that make vl binding proteins |
KR102306967B1 (en) | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
US10954310B2 (en) | 2010-08-02 | 2021-03-23 | Regeneran Pharmaceuticals, Inc. | Mice that make VL binding proteins |
KR20210118972A (en) * | 2010-08-02 | 2021-10-01 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
JP2016054746A (en) * | 2010-08-02 | 2016-04-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Mouse that makes binding protein comprising vl domain |
JP2019047805A (en) * | 2010-08-02 | 2019-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Mouse that makes binding protein comprising vl domain |
KR102163138B1 (en) | 2010-08-02 | 2020-10-08 | 리제너론 파아마슈티컬스, 인크. | Mice that make binding proteins comprising vl domains |
JP2013535213A (en) * | 2010-08-02 | 2013-09-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Mice producing a binding protein containing a VL domain |
JP2020078328A (en) * | 2010-08-02 | 2020-05-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Mouse that makes binding protein comprising vl domain |
US9686970B2 (en) | 2010-08-02 | 2017-06-27 | Regeneron Pharmaceuticals, Inc. | Mice that make VL binding proteins |
US8697940B2 (en) | 2011-02-25 | 2014-04-15 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2550363B1 (en) | 2011-02-25 | 2014-12-10 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
US10905108B2 (en) | 2011-02-25 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10905109B2 (en) | 2011-02-25 | 2021-02-02 | Regeneren Pharmaceuticals, Inc. | ADAM6 mice |
JP2014507137A (en) * | 2011-02-25 | 2014-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ADAM6 mouse |
JP2018143250A (en) * | 2011-02-25 | 2018-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Adam6 mice |
EP2550363A1 (en) | 2011-02-25 | 2013-01-30 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
EP2738259A3 (en) * | 2011-02-25 | 2014-07-30 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2738258B1 (en) | 2011-02-25 | 2019-09-25 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10072095B2 (en) | 2011-02-25 | 2018-09-11 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2813573A1 (en) * | 2011-02-25 | 2014-12-17 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US20140213773A1 (en) * | 2011-02-25 | 2014-07-31 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
JP2019187446A (en) * | 2011-02-25 | 2019-10-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Adam6 mice |
US8642835B2 (en) | 2011-02-25 | 2014-02-04 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
JP2022071051A (en) * | 2011-02-25 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Adam6 mice |
US9932408B2 (en) | 2011-02-25 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2578688A1 (en) | 2011-02-25 | 2013-04-10 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10694725B2 (en) | 2011-02-25 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP4067496A1 (en) * | 2011-02-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
JP2015107131A (en) * | 2011-02-25 | 2015-06-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ADAM6 mouse |
US10577430B2 (en) | 2011-02-25 | 2020-03-03 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2578688B1 (en) * | 2011-02-25 | 2019-07-24 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US9944716B2 (en) | 2011-02-25 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US11950578B2 (en) | 2011-02-25 | 2024-04-09 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
JP2014110814A (en) * | 2011-02-25 | 2014-06-19 | Regeneron Pharmaceuticals Inc | Adam6 mouse |
CN103429746A (en) * | 2011-02-25 | 2013-12-04 | 瑞泽恩制药公司 | ADAM6 mice |
EP2738258A3 (en) * | 2011-02-25 | 2014-09-24 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US20150201589A1 (en) * | 2011-02-25 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
EP3744850A1 (en) * | 2011-02-25 | 2020-12-02 | Regeneron Pharmaceuticals, Inc. | Adam6 mice |
EP3345922A1 (en) | 2011-03-09 | 2018-07-11 | Cell Signaling Technology, Inc. | Methods and reagents for creating monoclonal antibodies |
WO2012122484A1 (en) | 2011-03-09 | 2012-09-13 | Roberto Polakiewicz | Methods and reagents for creating monoclonal antibodies |
US11357217B2 (en) | 2011-08-05 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
EP3741862A1 (en) | 2011-09-19 | 2020-11-25 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
EP3128009B1 (en) | 2011-09-19 | 2020-07-29 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
CN103945689A (en) * | 2011-09-19 | 2014-07-23 | 科马布有限公司 | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
WO2013041846A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP3839049A2 (en) | 2011-09-19 | 2021-06-23 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
JP2016002084A (en) * | 2011-09-19 | 2016-01-12 | カイマブ・リミテッド | Antibodies, variable domains and chains tailored for human use |
EP3311661A1 (en) * | 2011-09-19 | 2018-04-25 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041844A3 (en) * | 2011-09-19 | 2013-07-11 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
EP4091442A1 (en) | 2011-09-19 | 2022-11-23 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041846A3 (en) * | 2011-09-19 | 2013-08-01 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2758534B1 (en) | 2011-09-19 | 2020-04-29 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
EP2758535B1 (en) | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
WO2013041845A3 (en) * | 2011-09-19 | 2013-08-08 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
EP2757875A2 (en) | 2011-09-19 | 2014-07-30 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2757875B1 (en) | 2011-09-19 | 2017-11-29 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP3128009A1 (en) * | 2011-09-19 | 2017-02-08 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
JP2014529998A (en) * | 2011-09-19 | 2014-11-17 | カイマブ・リミテッド | Antibodies, variable domains and chains made for human use |
EP3311661B1 (en) | 2011-09-19 | 2022-04-20 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
CN104024418B (en) * | 2011-10-17 | 2017-11-07 | 瑞泽恩制药公司 | Mouse with restricted heavy chain immunoglobulin |
US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
EP3216871A1 (en) * | 2011-10-17 | 2017-09-13 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
CN104024418A (en) * | 2011-10-17 | 2014-09-03 | 瑞泽恩制药公司 | Restricted immunoglobulin heavy chain mice |
JP2014531909A (en) * | 2011-10-17 | 2014-12-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Limited immunoglobulin heavy chain mice |
JP2020202873A (en) * | 2011-10-17 | 2020-12-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
EP4074833A1 (en) * | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
JP7022803B2 (en) | 2011-10-17 | 2022-02-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Mice with limited immunoglobulin heavy chains |
US11261248B2 (en) | 2011-10-17 | 2022-03-01 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
JP2016039820A (en) * | 2011-10-17 | 2016-03-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
EP2627773A1 (en) | 2011-10-17 | 2013-08-21 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
JP2019068836A (en) * | 2011-10-17 | 2019-05-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
JP2017221223A (en) * | 2011-10-17 | 2017-12-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9932398B2 (en) | 2011-10-17 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
KR101964776B1 (en) | 2011-10-28 | 2019-04-04 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
RU2661106C2 (en) * | 2011-10-28 | 2018-07-11 | Регенерон Фармасьютикалз, Инк. | Genetically modified t cell receptor mice |
KR20200102001A (en) * | 2011-10-28 | 2020-08-28 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
AU2012327204B2 (en) * | 2011-10-28 | 2016-01-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified T cell receptor mice |
US10986822B2 (en) | 2011-10-28 | 2021-04-27 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
KR102148387B1 (en) | 2011-10-28 | 2020-08-26 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
US10219493B2 (en) | 2011-10-28 | 2019-03-05 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
JP2019033770A (en) * | 2011-10-28 | 2019-03-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Genetically modified t-cell receptor mice |
JP2020146045A (en) * | 2011-10-28 | 2020-09-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Genetically modified t-cell receptor mice |
JP7305840B2 (en) | 2011-10-28 | 2023-07-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Genetically modified T cell receptor mouse |
US11219195B2 (en) | 2011-10-28 | 2022-01-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US11528895B2 (en) | 2011-10-28 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Genetically modified T cell receptor mice |
KR20180128494A (en) * | 2011-10-28 | 2018-12-03 | 리제너론 파아마슈티컬스, 인크. | Genetically modified major histocompatibility complex mice |
US10779520B2 (en) | 2011-10-28 | 2020-09-22 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
WO2013063361A1 (en) * | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
AU2016202512C1 (en) * | 2011-10-28 | 2018-10-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
KR20190037354A (en) * | 2011-10-28 | 2019-04-05 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
JP2014532413A (en) * | 2011-10-28 | 2014-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Genetically modified T cell receptor mouse |
AU2018204700B2 (en) * | 2011-10-28 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
EP3795587A1 (en) * | 2011-10-28 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
US9615550B2 (en) | 2011-10-28 | 2017-04-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US10045516B2 (en) | 2011-10-28 | 2018-08-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
US9700025B2 (en) | 2011-10-28 | 2017-07-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
AU2018204700C1 (en) * | 2011-10-28 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
CN113564188A (en) * | 2011-10-28 | 2021-10-29 | 瑞泽恩制药公司 | Method for preparing major histocompatibility complex gene modified mouse |
RU2797272C1 (en) * | 2011-10-28 | 2023-06-01 | Регенерон Фармасьютикалз, Инк. | Genetically modified mice for t-cell receptor |
US9113616B2 (en) | 2011-10-28 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice having humanized TCR variable genes |
US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
WO2013061078A1 (en) | 2011-10-28 | 2013-05-02 | Kymab Limited | Transgenic non-human assay vertebrates, assays & kits |
US10869466B2 (en) | 2011-10-28 | 2020-12-22 | Regeneran Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
KR102542272B1 (en) | 2011-10-28 | 2023-06-13 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
KR102397961B1 (en) | 2011-10-28 | 2022-05-13 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
KR20220066197A (en) * | 2011-10-28 | 2022-05-23 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
KR20210133325A (en) * | 2011-10-28 | 2021-11-05 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
CN104011071B (en) * | 2011-10-28 | 2017-11-07 | 瑞泽恩制药公司 | φt cell receptor genetic modification mouse |
CN107858332A (en) * | 2011-10-28 | 2018-03-30 | 瑞泽恩制药公司 | φt cell receptor genetic modification mouse |
CN107858333A (en) * | 2011-10-28 | 2018-03-30 | 瑞泽恩制药公司 | φt cell receptor genetic modification mouse |
IL274914B1 (en) * | 2011-10-28 | 2023-10-01 | Regeneron Pharma | Genetically modified t cell receptor mice |
CN107858333B (en) * | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T cell receptor gene modified mice |
AU2016202512B2 (en) * | 2011-10-28 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
EP3424947A1 (en) * | 2011-10-28 | 2019-01-09 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
CN104039132A (en) * | 2011-10-28 | 2014-09-10 | 瑞泽恩制药公司 | Genetically modified major histocompatibility complex mice |
US9585373B2 (en) | 2011-10-28 | 2017-03-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
CN104011071A (en) * | 2011-10-28 | 2014-08-27 | 瑞泽恩制药公司 | Genetically Modified T Cell Receptor Mice |
JP2022093637A (en) * | 2011-10-28 | 2022-06-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Genetically modified t-cell receptor mice |
JP2018007696A (en) * | 2011-10-28 | 2018-01-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Genetically modified t-cell receptor mice |
KR20140077219A (en) * | 2011-10-28 | 2014-06-23 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
KR102321909B1 (en) | 2011-10-28 | 2021-11-05 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
KR102074145B1 (en) | 2011-10-28 | 2020-02-07 | 리제너론 파아마슈티컬스, 인크. | Genetically modified major histocompatibility complex mice |
CN104160031B (en) * | 2011-12-02 | 2017-03-08 | 科马布有限公司 | For producing the fertile transgenic animal of the antibody with people variable region |
CN104160031A (en) * | 2011-12-02 | 2014-11-19 | 科马布有限公司 | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
EP4282879A2 (en) | 2011-12-02 | 2023-11-29 | Kymab Ltd. | Use of fertile transgenic animals for producing antibodies bearing human variable regions |
JP2018038428A (en) * | 2011-12-02 | 2018-03-15 | カイマブ・リミテッド | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
US20200205384A1 (en) * | 2011-12-02 | 2020-07-02 | Kymab Limited | Transgenic Animals |
WO2013061098A3 (en) * | 2011-12-02 | 2013-06-20 | Kymab Limited | Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes |
EP2989894A1 (en) * | 2011-12-02 | 2016-03-02 | Kymab Limited | Use of fertile transgenic animals for producing antibodies bearing human variable regions |
DE202012013369U1 (en) | 2011-12-02 | 2016-08-23 | Kymab Limited | Fertile transgenic animals useful for producing antibodies carrying human variable regions |
WO2013079953A1 (en) | 2011-12-02 | 2013-06-06 | Kymab Limited | Fertile transgenic animals useful for producing antibodies bearing human variable regions |
JP2015502149A (en) * | 2011-12-02 | 2015-01-22 | カイマブ・リミテッド | Breedable transgenic animals useful for producing antibodies carrying human variable regions |
EP3298889A1 (en) | 2011-12-02 | 2018-03-28 | Kymab Limited | Use of fertile transgenic animals for producing antibodies bearing human variable regions |
KR20190124339A (en) * | 2011-12-20 | 2019-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
KR102038974B1 (en) | 2011-12-20 | 2019-10-31 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
US11617357B2 (en) | 2011-12-20 | 2023-04-04 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
EP3527070A1 (en) * | 2011-12-20 | 2019-08-21 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
AU2017251797B2 (en) * | 2011-12-20 | 2019-12-05 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
AU2020201596B2 (en) * | 2011-12-20 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
JP7152447B2 (en) | 2011-12-20 | 2022-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | humanized light chain mouse |
KR102186822B1 (en) | 2011-12-20 | 2020-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
EP2793567A1 (en) | 2011-12-20 | 2014-10-29 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
JP2020168014A (en) * | 2011-12-20 | 2020-10-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized light chain mice |
JP2015502177A (en) * | 2011-12-20 | 2015-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized light chain mouse |
CN104159444A (en) * | 2011-12-20 | 2014-11-19 | 瑞泽恩制药公司 | Humanized light chain mice |
KR20200021552A (en) * | 2011-12-20 | 2020-02-28 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
US9706759B2 (en) | 2011-12-20 | 2017-07-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
JP7507823B2 (en) | 2011-12-20 | 2024-06-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Humanized Light Chain Mouse |
KR102081657B1 (en) | 2011-12-20 | 2020-02-26 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
RU2664181C2 (en) * | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Humanised light chain mice |
US10561124B2 (en) | 2011-12-20 | 2020-02-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
AU2012323987B2 (en) * | 2011-12-20 | 2015-07-09 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
JP2019047806A (en) * | 2011-12-20 | 2019-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized light chain mice |
KR101924805B1 (en) | 2011-12-20 | 2018-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
US11612151B2 (en) | 2011-12-20 | 2023-03-28 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
KR102156139B1 (en) | 2011-12-20 | 2020-09-15 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
KR20200108113A (en) * | 2011-12-20 | 2020-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
US9622459B2 (en) | 2011-12-20 | 2017-04-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
RU2761639C2 (en) * | 2011-12-20 | 2021-12-13 | Регенерон Фармасьютикалз, Инк. | Mice with humanized light chain |
KR20180132938A (en) * | 2011-12-20 | 2018-12-12 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized light chain mice |
WO2013096142A1 (en) * | 2011-12-20 | 2013-06-27 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US20170094955A1 (en) * | 2012-02-01 | 2017-04-06 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
US20210368751A1 (en) * | 2012-02-01 | 2021-12-02 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chain containing vl domains |
JP7525579B2 (en) | 2012-02-01 | 2024-07-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Humanized rodents expressing heavy chains containing VL domains |
US20130212719A1 (en) * | 2012-02-01 | 2013-08-15 | Regeneron Pharmaceuticals, Inc. | Humanized Rodents that Express Heavy Chain Containing VL Domains |
EP3165086A1 (en) * | 2012-03-06 | 2017-05-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
CN107090471A (en) * | 2012-03-06 | 2017-08-25 | 瑞泽恩制药公司 | Common light chain mouse |
WO2013134263A1 (en) * | 2012-03-06 | 2013-09-12 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
CN104244709A (en) * | 2012-03-06 | 2014-12-24 | 瑞泽恩制药公司 | Common light chain mouse |
US11224207B2 (en) | 2012-03-16 | 2022-01-18 | Regeneran Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US11192947B2 (en) | 2012-03-16 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating same |
US9648856B2 (en) | 2012-03-16 | 2017-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US9422370B2 (en) | 2012-03-16 | 2016-08-23 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9301510B2 (en) | 2012-03-16 | 2016-04-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with pH-dependent binding characteristics |
US9801362B2 (en) | 2012-03-16 | 2017-10-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
US9334334B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9332742B2 (en) | 2012-03-16 | 2016-05-10 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US9938358B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
JP2020176140A (en) * | 2012-03-28 | 2020-10-29 | カイマブ・リミテッド | Animal models and therapeutic molecules |
US9938357B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US10774155B2 (en) | 2012-03-28 | 2020-09-15 | Kymab Limited | Animal models and therapeutic molecules |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
JP2023009136A (en) * | 2012-03-28 | 2023-01-19 | カイマブ・リミテッド | Animal models and therapeutic molecules |
JP7475415B2 (en) | 2012-03-28 | 2024-04-26 | カイマブ・リミテッド | Animal models and therapeutic molecules |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
US9896516B2 (en) | 2012-03-28 | 2018-02-20 | Kymab Limited | Animal models and therapeutic molecules |
WO2013144566A2 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
JP2018119012A (en) * | 2012-03-28 | 2018-08-02 | カイマブ・リミテッド | Animal models and therapeutic molecules |
JP2015512634A (en) * | 2012-03-28 | 2015-04-30 | カイマブ・リミテッド | Animal models and therapeutic molecules |
EP3366126A1 (en) | 2012-03-28 | 2018-08-29 | Kymab Limited | Animal models and therapeutic molecules |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2501753A (en) * | 2012-05-04 | 2013-11-06 | Kymab Ltd | Human antibodies |
EP4116427A1 (en) | 2012-05-17 | 2023-01-11 | Kymab Limited | In vivo guided selection & antibodies |
GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US10542735B2 (en) | 2012-06-12 | 2020-01-28 | Regerneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JP2020110187A (en) * | 2012-06-12 | 2020-07-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20190006611A (en) * | 2012-06-12 | 2019-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102266274B1 (en) | 2012-06-12 | 2021-06-17 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20230012073A (en) * | 2012-06-12 | 2023-01-25 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US11559050B2 (en) | 2012-06-12 | 2023-01-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102484480B1 (en) | 2012-06-12 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US10238093B2 (en) | 2012-06-12 | 2019-03-26 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102650439B1 (en) | 2012-06-12 | 2024-03-26 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JP2015519076A (en) * | 2012-06-12 | 2015-07-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized non-human animals with limited immunoglobulin heavy chain loci |
KR20220123322A (en) * | 2012-06-12 | 2022-09-06 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102436654B1 (en) | 2012-06-12 | 2022-08-26 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JP2018029623A (en) * | 2012-06-12 | 2018-03-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JP7106596B2 (en) | 2012-06-12 | 2022-07-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
CN104540383A (en) * | 2012-06-12 | 2015-04-22 | 瑞泽恩制药公司 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20150027793A (en) * | 2012-06-12 | 2015-03-12 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US11666040B2 (en) | 2012-06-12 | 2023-06-06 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
JP2022090103A (en) * | 2012-06-12 | 2022-06-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20220044871A (en) * | 2012-06-12 | 2022-04-11 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102381716B1 (en) | 2012-06-12 | 2022-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20200126439A (en) * | 2012-06-12 | 2020-11-06 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20200074271A (en) * | 2012-06-12 | 2020-06-24 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR102126217B1 (en) | 2012-06-12 | 2020-06-24 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US9475859B2 (en) | 2012-12-14 | 2016-10-25 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
WO2014093908A3 (en) * | 2012-12-14 | 2014-10-16 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
US10385132B2 (en) | 2012-12-14 | 2019-08-20 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
KR20150094720A (en) * | 2012-12-14 | 2015-08-19 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
AU2018223041B2 (en) * | 2012-12-14 | 2020-06-25 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
EP2931030B1 (en) | 2012-12-14 | 2020-04-29 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
AU2013358958B2 (en) * | 2012-12-14 | 2018-09-20 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
JP2016505257A (en) * | 2012-12-14 | 2016-02-25 | オーエムティー,インコーポレイティド | Polynucleotide encoding rodent antibody having human idiotype and animal containing the same |
EP4269602A3 (en) * | 2012-12-14 | 2023-12-27 | OmniAB, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
KR102239125B1 (en) | 2012-12-14 | 2021-04-12 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
EP3653049A1 (en) * | 2012-12-14 | 2020-05-20 | Open Monoclonal Technology, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
CN105164153A (en) * | 2013-02-20 | 2015-12-16 | 瑞泽恩制药公司 | Mice expressing humanized T-cell co-receptors |
US9204624B2 (en) | 2013-02-20 | 2015-12-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modifed immunoglobulin heavy chain sequences |
US12063915B2 (en) | 2013-02-20 | 2024-08-20 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
US10820581B2 (en) | 2013-02-20 | 2020-11-03 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
US9930871B2 (en) | 2013-02-20 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
CN105164153B (en) * | 2013-02-20 | 2020-04-24 | 瑞泽恩制药公司 | Humanized T cell co-receptor mice |
US10154658B2 (en) | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US11224208B2 (en) | 2013-02-22 | 2022-01-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US10314296B2 (en) | 2013-02-22 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US10226033B2 (en) | 2013-03-18 | 2019-03-12 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US10730930B2 (en) | 2013-05-02 | 2020-08-04 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
EP3590539A1 (en) | 2014-03-04 | 2020-01-08 | Kymab Limited | Antibodies, uses & methods |
US11773175B2 (en) | 2014-03-04 | 2023-10-03 | Kymab Limited | Antibodies, uses and methods |
US11753479B2 (en) | 2014-03-04 | 2023-09-12 | Kymab Limited | Nucleic acids encoding anti-OX40L antibodies |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US10787522B2 (en) | 2014-03-21 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | VL antigen binding proteins exhibiting distinct binding characteristics |
WO2016063026A2 (en) | 2014-10-21 | 2016-04-28 | Kymab Ltd | Selective nav protein binders |
WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
EP4137157A1 (en) | 2015-03-03 | 2023-02-22 | Kymab Limited | Antibodies, uses and methods |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11259510B2 (en) | 2015-04-06 | 2022-03-01 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
US11889821B2 (en) | 2015-12-03 | 2024-02-06 | Trianni, Inc. | Enhanced immunoglobulin diversity |
US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
US11648308B2 (en) | 2016-05-03 | 2023-05-16 | Kymab Limited | Methods, regimens, combinations and antagonists |
WO2017210586A1 (en) | 2016-06-03 | 2017-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
EP4218408A1 (en) | 2016-06-03 | 2023-08-02 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
US10980221B2 (en) | 2016-06-03 | 2021-04-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
US10604576B2 (en) | 2016-06-20 | 2020-03-31 | Kymab Limited | Antibodies and immunocytokines |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
US9957323B2 (en) | 2016-06-20 | 2018-05-01 | Kymab Limited | Anti-ICOS antibodies |
WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
US11965026B2 (en) | 2016-06-20 | 2024-04-23 | Kymab Limited | Anti-PD-L1 and IL-2 cytokines |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US12016313B2 (en) | 2017-01-19 | 2024-06-25 | Omniab Operations, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
WO2018138297A1 (en) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anti-opg antibodies |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
WO2018189520A1 (en) * | 2017-04-10 | 2018-10-18 | Genome Research Limited | Animal models and therapeutic molecules |
GB2561352B (en) * | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
US11440960B2 (en) | 2017-06-20 | 2022-09-13 | Kymab Limited | TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo |
WO2018234575A1 (en) | 2017-06-22 | 2018-12-27 | Kymab Limited | Bispecific antibodies for factor ix and factor x |
US11051498B2 (en) | 2017-12-05 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Mouse having an engineered immunoglobulin lambda light chain |
WO2019122884A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Antibodies to icos |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
WO2019190922A1 (en) | 2018-03-24 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
WO2019241692A1 (en) | 2018-06-14 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
EP4023059A1 (en) | 2018-06-14 | 2022-07-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
WO2020049128A1 (en) | 2018-09-06 | 2020-03-12 | Kymab Limited | Antigen-binding molecules comprising unpaired variable domains |
WO2020065252A1 (en) | 2018-09-25 | 2020-04-02 | Kymab Limited | Antagonists |
WO2020128467A2 (en) | 2018-12-19 | 2020-06-25 | Kymab Limited | Antagonists |
US12004495B2 (en) | 2019-02-18 | 2024-06-11 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
US11730151B2 (en) | 2019-02-18 | 2023-08-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
WO2021105389A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
US11997994B2 (en) | 2020-06-02 | 2024-06-04 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
EP4173480A4 (en) * | 2020-06-25 | 2024-04-17 | Humab Co. Ltd. | Heterozygous transgenic animal |
WO2022056276A1 (en) | 2020-09-11 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
US12096753B2 (en) | 2020-10-22 | 2024-09-24 | Trianni, Inc. | Transgenic animals and methods of use |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
WO2022140219A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021200079B2 (en) | Animal models and therapeutic molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080040055.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10734546 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2010734546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2767436 Country of ref document: CA Ref document number: 2010269978 Country of ref document: AU Ref document number: 2012519063 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010269978 Country of ref document: AU Date of ref document: 20100707 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1163/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127003297 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012000536 Country of ref document: BR Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112012000536 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120109 |